Document:

EX-10.4

 Exhibit 10.4 
 REVANCE THERAPEUTICS, INC. 

STOCK OPTION GRANT NOTICE 

AMENDED AND RESTATED 

2012 EQUITY INCENTIVE PLAN 
 Revance Therapeutics, Inc. (the “Company”), pursuant to its Amended and Restated 2012 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an
option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in this notice, in the Option Agreement, the Plan and the Notice of Exercise, all of
which are attached hereto and incorporated herein in their entirety. Capitalized terms not explicitly defined herein but defined in the Plan or the Option Agreement will have the same definitions as in the Plan or the Option Agreement. If there is
any conflict between the terms in this notice and the Plan, the terms of the Plan will control. 
  

					
	Optionholder:	 	  
	 	
	Date of Grant:	 	  
	 	
	Vesting Commencement Date:	 	  
	 	
	Number of Shares Subject to Option:	 	  
	 	
	Exercise Price (Per Share):	 	  
	 	
	Total Exercise Price:	 	  
	 	
	Expiration Date:	 	  
	 	

  

					
	Type of Grant:	  	 ̈  Incentive Stock Option1	  	 ̈  Nonstatutory Stock Option
			
	Exercise Schedule:	  	 ̈  Same as Vesting Schedule	  	 ̈  Early Exercise Permitted
		
	Vesting Schedule:	  	One-fourth (1/4th) of the shares vest one year after the Vesting Commencement Date; the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary
of the Vesting Commencement Date, subject to Optionholder’s Continuous Service as of each such date.
		
	Payment:	  	By one or a combination of the following items (described in the Option Agreement):
		
		  	 ̈    By cash, check, bank draft or money order payable to the Company
		  	 ̈    Pursuant to a Regulation T Program if the shares are publicly traded
		  	 ̈    By delivery of already-owned shares if the shares are publicly traded

 Additional Terms/Acknowledgements: Optionholder acknowledges receipt of, and understands and agrees to, this Stock
Option Grant Notice, the Option Agreement and the Plan. Optionholder acknowledges and agrees that this Stock Option Grant Notice and the Option Agreement may not be modified, amended or revised except as provided in the Plan. Optionholder further
acknowledges that as of the Date of Grant, this Stock Option Grant Notice, the Option Agreement, and the Plan set forth the entire understanding between Optionholder and the Company regarding this option award and supersede all prior oral and
written agreements, promises and/or representations on that subject with the exception of (i) options previously granted and delivered to Optionholder, and (ii) the following agreements only. By accepting this option, you consent to
receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company. 

 

	1 	 If this is an Incentive Stock Option, it (plus other outstanding Incentive Stock Options) cannot be first exercisable for more than $100,000 in
value (measured by exercise price) in any calendar year. Any excess over $100,000 is a Nonstatutory Stock Option. 

											
		 	OTHER AGREEMENTS:	 	  

		 		 	  

				
	REVANCE THERAPEUTICS, INC.	 		 	OPTIONHOLDER:	 	
					
	By:	 	  
	 		 	  
	 	
		 	Signature	 		 	Signature	 	
						
	Title:	 	  
	 		 	Date:	 	  
	 	
						
	Date:	 	  
	 		 		 		 	

 ATTACHMENTS: Option Agreement, Amended and Restated 2012 Equity Incentive Plan and
Notice of Exercise 

 ATTACHMENT I 

OPTION AGREEMENT 

 REVANCE THERAPEUTICS, INC. 

AMENDED AND RESTATED 

2012 EQUITY INCENTIVE PLAN 

OPTION AGREEMENT 
 (INCENTIVE STOCK OPTION OR NONSTATUTORY STOCK OPTION) 

Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Option Agreement, Revance Therapeutics, Inc.
(the “Company”) has granted you an option under its Amended and Restated 2012 Equity Incentive Plan (the “Plan”) to purchase the number of shares of the Company’s Common Stock indicated in your
Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice (the “Date of Grant”). If there is any conflict between the terms
in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan. 

The details of your option, in addition to those set forth in the Grant Notice and the Plan, are as follows: 

1. VESTING. Your option will vest as provided in your Grant Notice. Vesting will cease upon the termination of your
Continuous Service. 
 2. NUMBER OF SHARES AND
EXERCISE PRICE. The number of shares of Common Stock subject to your option and your exercise price per share in your Grant Notice will be adjusted for Capitalization Adjustments. 

3. EXERCISE RESTRICTION FOR NON-EXEMPT
EMPLOYEES. If you are an Employee eligible for overtime compensation under the Fair Labor Standards Act of 1938, as amended (that is, a “Non-Exempt Employee”), and except as otherwise provided in the Plan,
you may not exercise your option until you have completed at least six (6) months of Continuous Service measured from the Date of Grant, even if you have already been an employee for more than six (6) months. Consistent with the provisions
of the Worker Economic Opportunity Act, you may exercise your option as to any vested portion prior to such six (6) month anniversary in the case of (i) your death or disability, (ii) a Corporate Transaction in which your option is
not assumed, continued or substituted, (iii) a Change in Control or (iv) your termination of Continuous Service on your “retirement” (as defined in the Company’s benefit plans). 

4. EXERCISE PRIOR TO VESTING (“EARLY
EXERCISE”). If permitted in your Grant Notice (i.e., the “Exercise Schedule” indicates “Early Exercise Permitted”) and subject to the provisions of your option, you may elect at any time that is
both (i) during the period of your Continuous Service and (ii) during the term of your option, to exercise all or part of your option, including the unvested portion of your option; provided, however, that: 

 (a) a partial exercise of your option will be deemed to cover first vested shares of
Common Stock and then the earliest vesting installment of unvested shares of Common Stock; 
 (b) any shares of Common
Stock so purchased from installments that have not vested as of the date of exercise will be subject to the purchase option in favor of the Company as described in the Company’s form of Early Exercise Stock Purchase Agreement; 

(c) you will enter into the Company’s form of Early Exercise Stock Purchase Agreement with a vesting schedule that will
result in the same vesting as if no early exercise had occurred; and 
 (d) if your option is an Incentive Stock Option,
then, to the extent that the aggregate Fair Market Value (determined at the Date of Grant) of the shares of Common Stock with respect to which your option plus all other Incentive Stock Options you hold are exercisable for the first time by you
during any calendar year (under all plans of the Company and its Affiliates) exceeds one hundred thousand dollars ($100,000), your option(s) or portions thereof that exceed such limit (according to the order in which they were granted) will be
treated as Nonstatutory Stock Options. 
 5. METHOD OF PAYMENT. You must pay
the full amount of the exercise price for the shares you wish to exercise. You may pay the exercise price in cash or by check, bank draft or money order payable to the Company or in any other manner permitted by your Grant Notice,
which may include one or more of the following: 
 (a) Provided that at the time of exercise the Common Stock is publicly
traded, pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable
instructions to pay the aggregate exercise price to the Company from the sales proceeds. This manner of payment is also known as a “broker-assisted exercise”, “same day sale”, or “sell to cover”. 

(b) Provided that at the time of exercise the Common Stock is publicly traded, by delivery to the Company (either by actual
delivery or attestation) of already-owned shares of Common Stock that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair Market Value on the date of exercise. “Delivery” for these
purposes, in the sole discretion of the Company at the time you exercise your option, will include delivery to the Company of your attestation of ownership of such shares of Common Stock in a form approved by the Company. You may not exercise your
option by delivery to the Company of Common Stock if doing so would violate the provisions of any law, regulation or agreement restricting the redemption of the Company’s stock. 

(c) If this option is a Nonstatutory Stock Option, subject to the consent of the Company at the time of exercise, by a “net
exercise” arrangement pursuant to which the Company will reduce the number of shares of Common Stock issued upon exercise of your option by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise
price. You must pay any remaining balance of the aggregate exercise price 

 
not satisfied by the “net exercise” in cash or other permitted form of payment. Shares of Common Stock will no longer be outstanding under your option and will not be exercisable
thereafter if those shares (i) are used to pay the exercise price pursuant to the “net exercise,” (ii) are delivered to you as a result of such exercise, and (iii) are withheld to satisfy your tax withholding obligations.

 6. WHOLE SHARES. You may exercise your option only for whole shares of Common Stock.

 7. SECURITIES LAW COMPLIANCE. In no event may you exercise your option
unless the shares of Common Stock issuable upon exercise are then registered under the Securities Act or, if not registered, the Company has determined that your exercise and the issuance of the shares would be exempt from the registration
requirements of the Securities Act. The exercise of your option also must comply with all other applicable laws and regulations governing your option, and you may not exercise your option if the Company determines that such exercise would not be in
material compliance with such laws and regulations (including any restrictions on exercise required for compliance with Treas. Reg. 1.401(k)-1(d)(3), if applicable). 
 8. TERM. You may not exercise your option before the Date of Grant or after the expiration of the option’s term. The term of your option expires, subject to the provisions of
Section 5(h) of the Plan, upon the earliest of the following: 
 (a) immediately upon the termination of your
Continuous Service for Cause; 
 (b) three (3) months after the termination of your Continuous Service for any
reason other than Cause, your Disability or your death (except as otherwise provided in Section 8(d) below); provided, however, that if during any part of such three (3) month period your option is not exercisable solely because of
the condition set forth in the section above relating to “Securities Law Compliance,” your option will not expire until the earlier of the Expiration Date or until it has been exercisable for an aggregate period of three (3) months
after the termination of your Continuous Service; provided further, if (i) you are a Non-Exempt Employee, (ii) your Continuous Service terminates within six (6) months after the Date of Grant, and (iii) you have vested in
a portion of your option at the time of your termination of Continuous Service, your option will not expire until the earlier of (x) the later of (A) the date that is seven (7) months after the Date of Grant, and (B) the date
that is three (3) months after the termination of your Continuous Service, and (y) the Expiration Date; 
 (c)
twelve (12) months after the termination of your Continuous Service due to your Disability (except as otherwise provided in Section 8(d)) below; 
 (d) eighteen (18) months after your death if you die either during your Continuous Service or within three (3) months after your Continuous Service terminates for any reason other than
Cause; 
 (e) the Expiration Date indicated in your Grant Notice; or 

(f) the day before the tenth (10th) anniversary of the Date of Grant. 

 If your option is an Incentive Stock Option, note that to obtain the federal income tax
advantages associated with an Incentive Stock Option, the Code requires that at all times beginning on the Date of Grant and ending on the day three (3) months before the date of your option’s exercise, you must be an employee of the
Company or an Affiliate, except in the event of your death or your permanent and total disability, as defined in Section 22(e)(3) of the Code. The Company has provided for extended exercisability of your option under certain circumstances for
your benefit but cannot guarantee that your option will necessarily be treated as an Incentive Stock Option if you continue to provide services to the Company or an Affiliate as a Consultant or Director after your employment terminates or if you
otherwise exercise your option more than three (3) months after the date your employment with the Company or an Affiliate terminates. 
 9. EXERCISE. 
 (a) You may exercise the vested
portion of your option (and the unvested portion of your option if your Grant Notice so permits) during its term by (i) delivering a Notice of Exercise (in a form designated by the Company) or completing such other documents and/or procedures
designated by the Company for exercise and (ii) paying the exercise price and any applicable withholding taxes to the Company’s Secretary, stock plan administrator, or such other person as the Company may designate, together with such
additional documents as the Company may then require. 
 (b) By exercising your option you agree that, as a condition to
any exercise of your option, the Company may require you to enter into an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of (i) the exercise of your option,
(ii) the lapse of any substantial risk of forfeiture to which the shares of Common Stock are subject at the time of exercise, or (iii) the disposition of shares of Common Stock acquired upon such exercise. 

(c) If your option is an Incentive Stock Option, by exercising your option you agree that you will notify the Company in writing
within fifteen (15) days after the date of any disposition of any of the shares of the Common Stock issued upon exercise of your option that occurs within two (2) years after the Date of Grant or within one (1) year after such shares
of Common Stock are transferred upon exercise of your option. 
 (d) By exercising your option you agree that you will
not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of
the Company held by you, for a period of one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request
to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rules or regulation (the “Lock-Up Period”); provided, however, that nothing contained in this section will prevent the
exercise of a repurchase option, if any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the
foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing 

 
covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until the end of such period. You also agree that any transferee of any shares of Common
Stock (or other securities) of the Company held by you will be bound by this Section 9(d). The underwriters of the Company’s stock are intended third party beneficiaries of this Section 9(d) and will have the right, power and
authority to enforce the provisions hereof as though they were a party hereto. 
 10. TRANSFERABILITY.
Except as otherwise provided in this Section 10, your option is not transferable, except by will or by the laws of descent and distribution, and is exercisable during your life only by you. 

(a) Certain Trusts. Upon receiving written permission from the Board or its duly authorized designee, you may transfer your option
to a trust if you are considered to be the sole beneficial owner (determined under Section 671 of the Code and applicable state law) while the option is held in the trust. You and the trustee must enter into transfer and other agreements
required by the Company. 
 (b) Domestic Relations Orders. Upon receiving written permission from the Board or its duly
authorized designee, and provided that you and the designated transferee enter into transfer and other agreements required by the Company, you may transfer your option pursuant to the terms of a domestic relations order, official marital settlement
agreement or other divorce or separation instrument as permitted by Treasury Regulation 1.421-1(b)(2) that contains the information required by the Company to effectuate the transfer. You are encouraged to discuss the proposed terms of any division
of this option with the Company prior to finalizing the domestic relations order or marital settlement agreement to help ensure the required information is contained within the domestic relations order or marital settlement agreement. If this option
is an Incentive Stock Option, this option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. 

(c) Beneficiary Designation. Upon receiving written permission from the Board or its duly authorized designee, you may, by
delivering written notice to the Company, in a form approved by the Company and any broker designated by the Company to handle option exercises, designate a third party who, on your death, will thereafter be entitled to exercise this option and
receive the Common Stock or other consideration resulting from such exercise. In the absence of such a designation, your executor or administrator of your estate will be entitled to exercise this option and receive, on behalf of your estate, the
Common Stock or other consideration resulting from such exercise. 
 11. RIGHT OF
FIRST REFUSAL. Shares of Common Stock that you acquire upon exercise of your option are subject to any right of first refusal that may be described in the Company’s bylaws in effect at such time the Company
elects to exercise its right. The Company’s right of first refusal will expire on the first date upon which any security of the Company is listed (or approved for listing) upon notice of issuance on a national securities exchange or quotation
system. 
 12. RIGHT OF REPURCHASE. To the extent provided in the
Company’s bylaws in effect at such time the Company elects to exercise its right, the Company will have the right to 

 
repurchase all or any part of the shares of Common Stock you acquire pursuant to the exercise of your option. 
 13. OPTION NOT A SERVICE CONTRACT. Your option is not an employment or service contract, and nothing in your option will
be deemed to create in any way whatsoever any obligation on your part to continue in the employ of the Company or an Affiliate, or of the Company or an Affiliate to continue your employment. In addition, nothing in your option will obligate the
Company or an Affiliate, their respective stockholders, boards of directors, officers or employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate. 

14. WITHHOLDING OBLIGATIONS. 

(a) At the time you exercise your option, in whole or in part, and at any time thereafter as requested by the Company, you hereby
authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for (including by means of a “same day sale” pursuant to a program developed under Regulation T as promulgated by the
Federal Reserve Board to the extent permitted by the Company), any sums required to satisfy the federal, state, local and foreign tax withholding obligations of the Company or an Affiliate, if any, which arise in connection with the exercise of your
option. 
 (b) If this option is a Nonstatutory Stock Option, then upon your request and subject to approval by the
Company, and compliance with any applicable legal conditions or restrictions, the Company may withhold from fully vested shares of Common Stock otherwise issuable to you upon the exercise of your option a number of whole shares of Common Stock
having a Fair Market Value, determined by the Company as of the date of exercise, not in excess of the minimum amount of tax required to be withheld by law (or such lower amount as may be necessary to avoid classification of your option as a
liability for financial accounting purposes). If the date of determination of any tax withholding obligation is deferred to a date later than the date of exercise of your option, share withholding pursuant to the preceding sentence shall not be
permitted unless you make a proper and timely election under Section 83(b) of the Code, covering the aggregate number of shares of Common Stock acquired upon such exercise with respect to which such determination is otherwise deferred, to
accelerate the determination of such tax withholding obligation to the date of exercise of your option. Notwithstanding the filing of such election, shares of Common Stock shall be withheld solely from fully vested shares of Common Stock determined
as of the date of exercise of your option that are otherwise issuable to you upon such exercise. Any adverse consequences to you arising in connection with such share withholding procedure shall be your sole responsibility. 

(c) You may not exercise your option unless the tax withholding obligations of the Company and/or any Affiliate are satisfied.
Accordingly, you may not be able to exercise your option when desired even though your option is vested, and the Company will have no obligation to issue a certificate for such shares of Common Stock or release such shares of Common Stock from any
escrow provided for herein, if applicable, unless such obligations are satisfied. 

 15. TAX CONSEQUENCES. You hereby agree
that the Company does not have a duty to design or administer the Plan or its other compensation programs in a manner that minimizes your tax liabilities. You will not make any claim against the Company, or any of its Officers, Directors, Employees
or Affiliates related to tax liabilities arising from your option or your other compensation. In particular, you acknowledge that this option is exempt from Section 409A of the Code only if the exercise price per share specified in the Grant
Notice is at least equal to the “fair market value” per share of the Common Stock on the Date of Grant and there is no other impermissible deferral of compensation associated with the option. Because the Common Stock is not traded on an
established securities market, the Fair Market Value is determined by the Board, perhaps in consultation with an independent valuation firm retained by the Company. You acknowledge that there is no guarantee that the Internal Revenue Service will
agree with the valuation as determined by the Board, and you will not make any claim against the Company, or any of its Officers, Directors, Employees or Affiliates in the event that the Internal Revenue Service asserts that the valuation determined
by the Board is less than the “fair market value” as subsequently determined by the Internal Revenue Service. 

16. NOTICES. Any notices provided for in your option or the Plan will be given in writing (including
electronically) and will be deemed effectively given upon receipt or, in the case of notices delivered by mail by the Company to you, five (5) days after deposit in the United States mail, postage prepaid, addressed to you at the last address
you provided to the Company. The Company may, in its sole discretion, decide to deliver any documents related to participation in the Plan and this option by electronic means or to request your consent to participate in the Plan by electronic means.
By accepting this option, you consent to receive such documents by electronic delivery and to participate in the Plan through an on-line or electronic system established and maintained by the Company or another third party designated by the Company.

 17. GOVERNING PLAN DOCUMENT. Your option is subject to all the provisions
of the Plan, the provisions of which are hereby made a part of your option, and is further subject to all interpretations, amendments, rules and regulations, which may from time to time be promulgated and adopted pursuant to the Plan. If there is
any conflict between the provisions of your option and those of the Plan, the provisions of the Plan will control. In addition, your option (and any compensation paid or shares issued under your option) is subject to recoupment in accordance with
The Dodd–Frank Wall Street Reform and Consumer Protection Act and any implementing regulations thereunder, any clawback policy adopted by the Company and any compensation recovery policy otherwise required by applicable law. 

18. EFFECT ON OTHER EMPLOYEE BENEFIT
PLANS. The value of this option will not be included as compensation, earnings, salaries, or other similar terms used when calculating your benefits under any employee benefit plan sponsored by the Company or any
Affiliate, except as such plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify, or terminate any of the Company’s or any Affiliate’s employee benefit plans. 

19. VOTING RIGHTS. You will not have voting or any other rights as a stockholder of
the Company with respect to the shares to be issued pursuant to this option until such shares are issued to you. Upon such issuance, you will obtain full voting and other rights as a stockholder of the Company. Nothing contained in this option, and
no action taken pursuant to its 

 
provisions, will create or be construed to create a trust of any kind or a fiduciary relationship between you and the Company or any other person. 

20. SEVERABILITY. If all or any part of this Option Agreement or the Plan is declared by any court
or governmental authority to be unlawful or invalid, such unlawfulness or invalidity will not invalidate any portion of this Option Agreement or the Plan not declared to be unlawful or invalid. Any Section of this Option Agreement (or part of such a
Section) so declared to be unlawful or invalid shall, if possible, be construed in a manner which will give effect to the terms of such Section or part of a Section to the fullest extent possible while remaining lawful and valid. 

21. MISCELLANEOUS. 
 (a) The rights and obligations of the Company under your option will be transferable to any one or more persons or entities, and all covenants and agreements hereunder will inure to the benefit of,
and be enforceable by the Company’s successors and assigns. 
 (b) You agree upon request to execute any further
documents or instruments necessary or desirable in the sole determination of the Company to carry out the purposes or intent of your option. 
 (c) You acknowledge and agree that you have reviewed your option in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting your option, and fully
understand all provisions of your option. 
 (d) This Option Agreement will be subject to all applicable laws, rules, and
regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required. 
 (e)
All obligations of the Company under the Plan and this Option Agreement will be binding on any successor to the Company, whether the existence of such successor is the result of a direct or indirect purchase, merger, consolidation, or otherwise,
of all or substantially all of the business and/or assets of the Company. 

*        *        * 

This Option Agreement will be deemed to be signed by you upon the signing by 

you of the Stock Option Grant Notice to which it is attached. 

 ATTACHMENT II 

REVANCE THERAPEUTICS, INC. 

AMENDED AND RESTATED 2012 EQUITY INCENTIVE
PLAN 

 ATTACHMENT III 

NOTICE OF EXERCISE 

 NOTICE OF EXERCISE 
 Revance Therapeutics, Inc. 
 7555 Gateway Boulevard, Suite 100 

Newark, California 94560 

Date of Exercise:
                     
 This
constitutes notice to Revance Therapeutics, Inc. (the “Company”) under my stock option that I elect to purchase the below number of shares of Common Stock of the Company (the “Shares”) for the
price set forth below. 
  

									
	 Type of option (check one):
	  	 	Incentive  ̈	  	  	 	Nonstatutory  ̈	  
			
	 Stock option dated:
	  				  			
		  	  
	  
	 	  	  
	  
	 
			
	 Number of Shares as to which option is exercised:
	  				  			
		  	  
	  
	 	  	  
	  
	 
			
	 Certificates to be issued in name of:
	  				  			
		  	  
	  
	 	  	  
	  
	 
			
	 Total exercise price:
	  	$	            	  	  	$	            	  
			
	 Cash payment delivered herewith:
	  	$	            	  	  	$	            	  
			
	 Value of                  Shares delivered
herewith2:
	  	$	            	  	  	$	            	  
			
	 Regulation T Program (cashless exercise3):
	  	$	            	  	  	$	            	  

 By this exercise, I agree (i) to provide such additional documents as you may require pursuant to
the terms of the Revance Therapeutics, Inc. Amended and Restated 2012 Equity Incentive Plan, (ii) to provide for the payment by me to you (in the manner designated by you) of 

 

	2 	Shares must meet the public trading requirements set forth in the option. Shares must be valued in accordance with the terms of the option being exercised, and must be
owned free and clear of any liens, claims, encumbrances or security interests. Certificates must be endorsed or accompanied by an executed assignment separate from certificate. 

	3 	Shares must meet the public trading requirements set forth in the option 

  
 1. 

 
your withholding obligation, if any, relating to the exercise of this option, and (iii) if this exercise relates to an incentive stock option, to notify you in writing within fifteen
(15) days after the date of any disposition of any of the Shares issued upon exercise of this option that occurs within two (2) years after the date of grant of this option or within one (1) year after such Shares are issued upon
exercise of this option. 
 I hereby make the following certifications and representations with respect to the number of Shares
listed above, which are being acquired by me for my own account upon exercise of the option as set forth above: 
 I acknowledge
that the Shares have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and are deemed to constitute “restricted securities” under Rule 701 and Rule 144 promulgated under the
Securities Act. I warrant and represent to the Company that I have no present intention of distributing or selling said Shares, except as permitted under the Securities Act and any applicable state securities laws. 

I further acknowledge that I will not be able to resell the Shares for at least ninety (90) days after the stock of the Company
becomes publicly traded (i.e., subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934) under Rule 701 and that more restrictive conditions apply to affiliates of the Company under Rule 144.

 I further acknowledge that all certificates representing any of the Shares subject to the provisions of the Option shall have
endorsed thereon appropriate legends reflecting the foregoing limitations, as well as any legends reflecting restrictions pursuant to the Company’s Articles of Incorporation, Bylaws and/or applicable securities laws. 

I further agree that, if required by the Company (or a representative of the underwriters) in connection with the first underwritten
registration of the offering of any securities of the Company under the Securities Act, I will not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the
same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company for a period of one hundred eighty (180) days following the effective date of a registration statement of the Company filed under the
Securities Act (or such longer period as the underwriters or the Company shall request to facilitate compliance with FINRA Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation) (the “Lock-Up
Period”). I further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In
order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such period. 

 

	
	Very truly yours,
	
	  

  
 2.EX-10.14

 Exhibit 10.14 
 EXECUTION VERSION 
 CONFIDENTIAL 

SETTLEMENT AND TERMINATION AGREEMENT 
 THIS SETTLEMENT AND TERMINATION AGREEMENT (“Termination Agreement”) dated as of October 8, 2012 (“Execution Date”), is entered into between Revance Therapeutics,
Inc., a Delaware corporation having its principal place of business at 7555 Gateway Blvd., Newark, CA 94560 (“Revance”) and Medicis Pharmaceutical Corporation, a Delaware corporation with offices at 7720 North Dobson Road,
Scottsdale, AZ 85256 (“Medicis”). 
 BACKGROUND 

A. The Parties (as hereinafter defined) entered into that certain Option Agreement dated December 11, 2007 (“Option
Agreement”), pursuant to which Revance granted to Medicis an option either to: (1) acquire Revance entirely pursuant to a Merger Agreement among the Parties, RTI Acquisition Corporation, Inc. and Robert Byrnes, as the Escrow
Representative dated December 11, 2007 attached as an exhibit to the Option Agreement (“Merger Agreement”); or (2) obtain a certain license to develop and commercialize certain topical botulinum toxin products, including
Revance’s product candidate known as RT001, on the terms set forth in a License Agreement between the Parties dated December 11, 2007 also attached as an exhibit to the Option Agreement (the “RT001 License Agreement”), all
in accordance with the terms of the Option Agreement; 
 B. The Parties also entered into that certain License Agreement dated
July 27, 2009 (“RT002 License Agreement”) pursuant to which Revance granted to Medicis a certain license to develop and commercialize certain injectable botulinum toxin products, including Revance’s Product candidate known
as RT002, in accordance with the terms of the RT002 License Agreement. 
 C. Revance and Medicis are also parties to that
certain Series C-1, C-2 and C-3 Preferred Stock Purchase Agreement dated December 11, 2007 (the “Series C Preferred Stock Purchase Agreement”), Revance Series D Preferred Stock Purchase Agreement dated December 8, 2009
(the “Series D Preferred Stock Purchase Agreement”), Revance Investor Rights Agreement, Revance Co-Sale Agreement, and Revance Voting Agreement, which agreements were entered into in connection with Medicis’ purchase of shares
of Series C-3 Preferred Stock and Series D Preferred Stock of Revance. 
 D. Revance and Medicis are currently parties to a
litigation pertaining to the Option Agreement and RT001 License Agreement now pending in the Chancery Court of the State of Delaware captioned Revance Therapeutics, Inc. v. Medicis Pharmaceutical Corporation, C.A. No.: 7549-VCL (the
“Litigation”); 
 E. Without making any admission of liability or concession on strength of their respective
claims, the Parties deem it to be in their best interests and to their mutual advantage to (i) settle the Litigation, (ii) terminate the Option Agreement, the RT001 License Agreement, the Merger Agreement and the RT002 License Agreement,
and (iii) take such other actions as are provided herein, all on the terms and conditions set forth in this Termination Agreement. 

  
 - 1 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 NOW, THEREFORE, in consideration of all of the terms and conditions of this Termination
Agreement, the Parties agree as follows: 
 ARTICLE I 

DEFINITIONS 
 As used in this Termination Agreement, the following capitalized terms will have the meanings set forth in this Article I when used in this Termination Agreement. 

1.1 “Acceleration Transaction” shall mean each of the following: 

(a) a Change of Control; 
 (b) an Initial Public Offering in which shares of Revance’s capital stock owned by stockholders of Revance are included in and sold pursuant to the Initial Public Offering; 

(c) a transaction (other than a Change of Control) in which Revance grants to a Third Party rights to commercialize either or both of
RT001 or RT002, and as part of such transaction (or series of related transactions), Revance distributes Cash Proceeds from such transaction to any Revance stockholder, other than nonemployee advisors or consultants as a fee for services in
connection with such transaction. For the avoidance of doubt, the grant of such commercialization rights alone shall not constitute an Acceleration Transaction so long as the Cash Proceeds of such transaction are not so distributed to Revance
stockholders; 
 (d) making any cash dividend or other cash distribution or otherwise making any payment in cash or Marketable
Securities to any Revance stockholder in respect of shares of Revance’s Preferred Stock, other than a cumulative total (prior to payment in full of the Second Payment Amount) of distributions or payments made to repurchase shares held by
stockholders who collectively own less than ten percent (10%) of the total outstanding shares of Revance Preferred Stock as of the Execution Date (determined on an as-converted basis, based on the number of shares of Common Stock issuable upon
such conversion); 
 (e) making any payment in cash or Marketable Securities to any Revance stockholder on account of
convertible debt securities of Revance, to the extent such debt securities exist as of the Execution Date; and 
 (f) paying
cumulative bonus payments in cash or Marketable Securities to employees who are Revance stockholders in any year in excess of Four Million Dollars (US $4,000,000) (prior to payment in full of the Second Payment Amount). 

  
 - 2 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 1.2 “Affiliate” of a Party shall mean any Person that, directly or
indirectly through one or more intermediaries, controls, is controlled by or is under common control with such Party, as the case may be, for as long as such control exists. As used in this Section 1.2, “control” shall mean:
(a) to possess, directly or indirectly, the power to direct the management and policies of such Person, whether through ownership of voting securities or by contract relating to voting rights or corporate governance; or (b) direct or
indirect beneficial ownership of at least fifty percent (50%) (or such lesser percentage that is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital in such Person. 

1.3 “Applicable Laws” means the applicable provisions of any and all national, supranational, regional, state and local
laws, treaties, statutes, rules, regulations, administrative codes, guidances, ordinances, judgments, decrees, directives, injunctions, orders, permits (including Marketing Approvals) of or from any court, arbitrator, Regulatory Authority or
governmental agency or authority having jurisdiction over or related to the subject item. 
 1.4 “BLA” means a
Biologics License Application as defined in the United States Federal Food, Drug and Cosmetics Act and the regulations promulgated thereunder, or similar application filed with a Regulatory Authority. 

1.5 “Cash Proceeds” shall mean any and all cash payments and Marketable Securities that Revance, its Affiliates and its
and their successors and assigns receive following the Execution Date and shall include any amounts paid by a Third Party in satisfaction of debts of Revance, excluding (i) funds received in connection with any refinancing of the Existing
Hercules Debt, up to the Refinanced Amount, (ii) the first Seven Million Dollars (US $7,000,000) of cash payments or Marketable Securities received by Revance after the Execution Date provided that all such amounts are paid to Medicis as the
Upfront Payment, and (iii) funds received in connection with an equipment financing up to the cost of the equipment and the soft costs directly related to the equipment and facility improvements directly related to the purchase of such
equipment being financed (e.g., maintenance and installation costs and other capitalized equipment or associated facilities related costs). Notwithstanding the foregoing, Cash Proceeds will be calculated net of amounts due to the payor of such Cash
Proceeds or legally required to be withheld by the payor from such Cash Proceeds that are in fact deducted or withheld (including withholding taxes) from the amount of such Cash Proceeds, and net of any underwriter or placement agent fees, discounts
and commissions and offering expenses paid to Third Parties (other than the payor of the Cash Proceeds) directly in connection with raising such proceeds in a public offering or private placement of securities. For clarity, neither the conversion of
notes or other securities issued by Revance prior to the Execution Date (i.e., to the extent no cash payment or Marketable Securities are first received by Revance after the Execution Date as a result of such conversion) nor the value of any
non-cash consideration (other than Marketable Securities) received by Revance shall be considered Cash Proceeds. For clarity, cash payments and Marketable Securities received by Affiliates, successors and assigns shall be included in Cash
Proceeds only to the extent the same are received after the date such entities become an Affiliate, successor or assign of Revance. 

  
 - 3 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 1.6 “Change of Control” shall mean: 

(a) Either: (A) a consolidation or merger of Revance with or into, or any other corporate reorganization with, a Qualified Third
Party; or (B) any transaction or series of related transactions to which Revance is a party in which in excess of fifty percent (50%) of Revance’s voting power is transferred to a Qualified Third Party; in each of cases (A) and
(B), where the security holders of Revance (in the aggregate) immediately prior to such consolidation, merger, reorganization or transaction, own less than fifty percent (50%) of the voting power of the surviving entity immediately after such
consolidation, merger, reorganization or transaction; 
 (b) a sale, lease or other transfer to one or more Third Parties of all
or substantially all of the assets of Revance; or 
 (c) a sale, lease or other transfer to one or more Third Parties of all or
substantially all rights to RT001 Products for substantially all uses in the United States and at least three Major EU Markets. For the avoidance of doubt, and without limiting the foregoing: (i) a sale, lease or other transfer of all or
substantially all rights for substantially all uses in the United States and at least three Major EU Markets to Revance’s topical botulinum toxin product candidate known as RT001 described in US IND number 100053 (“Existing RT001
Product”) shall constitute a Change of Control; and (ii) with respect to the Existing RT001 Product (x) the fields of aesthetic indications and hyperhidrosis shall together constitute substantially all uses and (y) the grant of
any of the following for substantially all uses shall constitute substantially all rights: (1) exclusive commercialization rights or (2) the grant of exclusive rights with respect to the applicable BLA(s), the applicable data or the
applicable patent rights for such uses; 
 The Parties agree that a merger, corporate reorganization, issuance of shares or other transfer of
voting power shall not be deemed a “sale, lease or other transfer” for purposes of subparagraphs (ii) or (iii) above. 
 1.7 “Claims” shall mean any and all claims, actions, causes of action, demands, costs, grievances, duties, obligations, rights, counterclaims, debts, damages, losses, liabilities,
judgments, and charges of whatever nature, whether known or unknown. 
 1.8 “Existing Hercules Debt” shall mean
the principal amount (and any premium thereon), plus accrued and unpaid interest thereon and any fees and expenses and other amounts due, owed by Revance to Hercules Technology Growth Capital, Inc. (“Hercules Capital”)
pursuant to that certain Loan and Security Agreement, dated as of September 20, 2011, as amended, restated, supplemented or otherwise modified from time to time, and any documents related thereto (the “Hercules Loan”). If
Revance refinances or increases the amount of the Existing Hercules Debt, references herein to Existing Hercules Debt shall include the principal of (and premium, if any), unpaid interest on and amounts reimbursable, fees, expenses, and other
amounts due in connection with indebtedness for borrowed money of Revance, to banks, commercial finance lenders or other lending institutions regularly engaged in the business of lending money, including Hercules Capital, in connection with such
refinancing and any increase, extension, refinance, renewal, replacement, defeasance or refunding thereof (each, a “Refinanced Loan”). 

  
 - 4 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 1.9 “FDA” shall mean the United States Food and Drug Administration, or
any successor entity thereto performing similar functions. 
 1.10 “Initial Public Offering” shall mean an
initial public offering pursuant to an effective registration statement on Form S-1 (or any similar successor form) under the Securities Act of 1933, as amended, covering the offer and sale of securities of Revance. 

1.11 “Limited Initial Public Offering” shall mean an Initial Public Offering from which the Cash Proceeds to Revance are
less than Sixty Million Dollars (US $60,000,000). 
 1.12 “Major EU Market” shall mean any of the United
Kingdom, France, Germany, Italy or Spain. 
 1.13 “Marketable Securities” shall mean unrestricted securities
that are listed and currently tradeable on NASDAQ or a national securities exchange, or are freely negotiable commercial paper, Treasury bills, and money market instruments. 
 1.14 “Marketing Approval” shall mean receipt of all requisite approvals, licenses, registrations or authorizations of the Regulatory Authority in a country necessary for the marketing of
a Product in such country, but shall not include price or reimbursement or manufacturing approvals. For clarity, the approval of a BLA by the applicable Regulatory Authority shall constitute Marketing Approval. “Party” shall mean
Revance or Medicis individually, and “Parties” shall mean Revance and Medicis collectively. 
 1.15
“Person” means any individual, corporation, partnership, firm, association, joint venture, joint stock company, trust or other entity, or any government or regulatory administrative or political subdivision or agency, department or
instrumentality thereof. 
 1.16 “Product” shall mean either RT001 or RT002. 

1.17 “Qualified Third Party” shall mean any entity that, for the most recent Relevant Accounting Period of such Third
Party completed prior to the announcement of a Change of Control, had either (a) Net Cash, as of the end of such Relevant Accounting Period, equal to or exceeding the Qualifying Threshold or (b) annual consolidated revenues (with its
consolidating affiliates) equal to or exceeding two times the Qualifying Threshold. Any entity controlled (as defined in Section 1.2 above) by such entity shall be deemed to be a Qualified Third Party. Promptly following the consummation of any
Change of Control, Revance shall provide Medicis with audited financial statements of the Qualified Third Party for the most recent fiscal year completed prior to the announcement of a Change of Control. For such purposes, “Relevant Accounting
Period” shall mean, with respect to 1.17(a) above, the most recent fiscal quarter, and with respect to 1.17(b) 

  
 - 5 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 
above, the most recent fiscal year; and “Net Cash” shall mean (i) cash and cash equivalents (including Marketable Securities) plus accounts receivable, less
(ii) current liabilities, as reflected in the financial statements for the Relevant Accounting Period. “Qualifying Threshold” shall mean an amount equal to the Acceleration Balance Amount (as defined in 3.2(b) below)
immediately prior to consummation of the Change of Control divided by 0.15. 
 1.18 “Refinanced Amount” shall
mean (i) US $20,247,722.58; plus (ii) if Revance refinances or increases the amount of a Refinanced Loan, the amount of Cash Proceeds that Revance received pursuant to such prior Refinanced Loan (and for which a Proceeds Sharing Payment
was paid under Section 3.2 below). For example, if Revance refinances the Hercules Loan and replaces it with a Refinanced Loan in the amount of US $25,000,000, then for purposes of such refinancing, the Refinanced Amount would be US
$20,247,722.58 and the sum of US $4,752,277.42 (or US $25,000,000 minus US $20,247,722.58) would constitute Cash Proceeds. If Revance subsequently refinances such Refinanced Loan, then the Refinanced Amount for purposes of the subsequent refinancing
would be US $25,000,000. 
 1.19 “Regulatory Authority” shall mean the FDA, or a regulatory body with similar
authority in any other jurisdiction. 
 1.20 “RT001” shall mean any “Product” as defined in the RT001
License Agreement, including Revance’s topical botulinum toxin product candidate known as RT001 described in US IND number 100053. 
 1.21 “RT002” shall mean any “Product” as defined in the RT002 License Agreement. 
 1.22 “Third Party” shall mean any Person other than Revance, Medicis and their respective Affiliates. 
 ARTICLE II 
 TERMINATION OF TERMINATED AGREEMENTS; RELEASE; DISMISSAL

 2.1 Termination of Terminated Agreements. Revance and Medicis hereby agree that each of the Option Agreement, the
Merger Agreement, the RT001 License Agreement and the RT002 License Agreement (collectively, the “Terminated Agreements”) is hereby terminated in its entirety and shall be of no further force or effect as of the Termination
Effective Date. The termination of the Option Agreement hereunder shall be deemed to be a termination thereof by mutual written consent of the Parties pursuant to Section 2.1(a) of the Option Agreement, accordingly, the Merger Agreement shall
be deemed terminated pursuant to Section 6.1(a) of the Merger Agreement, and the RT001 License Agreement shall be deemed terminated pursuant to Section 10.2 of the RT001 License Agreement. The termination of the RT002 License Agreement
hereunder shall be deemed to be a termination thereof pursuant to Section 9.2(a) of the RT002 License Agreement by mutual written agreement of the Parties. The Parties hereby waive all rights

  
 - 6 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 
to notice of termination as may be otherwise provided under the Terminated Agreements or Applicable Laws. It is understood that Revance may retain any amounts previously paid to it under the
Terminated Agreements. 
 2.2 Effect of Termination. Revance and Medicis further agree that the survival provisions set
forth in Section 10.7 of the RT001 License Agreement, in Section 8 of the Merger Agreement and in Section 9.6 of the RT002 License Agreement, are hereby amended to negate the effect thereof, so that no right, obligation or provision
of the Terminated Agreements survives or otherwise remains in effect after the Termination Effective Date. For the avoidance of doubt, notwithstanding any other provision of the RT001 License Agreement (including Section 10.7 thereof), the
Merger Agreement (including Section 8 thereof) or the RT002 License Agreement (including Section 9.6 thereof) none of the provisions of the Terminated Agreements shall be deemed to survive, all licenses and rights granted by Revance to
Medicis under the Terminated Agreements shall terminate immediately and revert back to Revance, Medicis shall have no rights or obligations with respect to either Product, and neither the Option Agreement, the Merger Agreement, the RT001 License
Agreement nor the RT002 License Agreement (nor any provision thereof) shall have any force or effect whatsoever. 
 2.3
Release. Except with respect to the obligations created by, acknowledged, or arising out of this Termination Agreement, as of the Termination Effective Date each Party does hereby for itself and its respective legal predecessors, successors
and assigns, and its Affiliates, and each of their respective current and former trustees, officers, directors, employees, agents, attorneys, and representatives, unconditionally release, covenant not to sue, and absolutely and forever discharge the
other Party, together with its respective legal predecessors, successors and assigns, and its Affiliates, and each of their respective current and former trustees, officers, directors, employees, agents, attorneys, and representatives, from any and
all Claims existing or arising from acts, omissions or circumstances existing as of the Termination Effective Date, whether known or unknown, anticipated or unanticipated, whether at law or in equity, which either Party may have or claim to have
against the other Party or the other Persons identified above in the past, now or at any time in the future based on such Claims, including any and all claims for attorneys’ fees and costs (all of which are hereinafter referred to as and
included within the “Released Matters”). It is the intention of the Parties in executing this Termination Agreement that this Termination Agreement will be effective as a full and final accord and satisfaction and mutual general
release of and from all Released Matters. 
 2.4 Unknown Claims. In furtherance of the intentions set forth herein, each
of the Parties acknowledges that it is familiar with Section 1542 of the Civil Code of the State of California which provides as follows: 
 “A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM MUST HAVE MATERIALLY
AFFECTED HIS SETTLEMENT WITH THE DEBTOR.” 

  
 - 7 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 Each Party expressly waives and relinquishes any right or benefit which it has or may have under
Section 1542 of the Civil Code of the State of California and any and all provisions, rights and benefits to similar effect conferred by any law of any state or territory of the United States or foreign country or principle of common or civil
law. In connection with such waiver and relinquishment, each of the Parties acknowledges that it is aware that it or its attorneys or accountants may hereafter discover claims or facts in addition to or different from those which it now knows or
believes to exist with respect to the subject matter of this Termination Agreement or the other Party hereto, but that its intention hereby is to fully, finally and forever settle and release all of the Released Matters, disputes and differences
known or unknown, suspected or unsuspected, which now exist, may exist or heretofore have existed between the Parties, except as otherwise expressly provided. In furtherance of this intention, the releases herein given will be and remain in effect
as full and complete mutual releases notwithstanding the discovery or existence of any such additional or different claim or fact. 
 2.5 Dismissal. Revance and Medicis each covenant and agree that within three (3) business days of execution of this Termination Agreement they will each seek dismissal with prejudice of all
claims and/or counterclaims in the Litigation, by filing a motion to dismiss or by following such other procedures which may be reasonably necessary to dismiss with prejudice all claims and counterclaims in the lawsuit. 

ARTICLE III 

FINANCIAL TERMS 
 3.1 Upfront Payment. Revance shall pay to Medicis an amount equal to Seven Million Dollars (US $7,000,000) (the “Upfront Payment”) within thirty (30) days following the
Execution Date. The date such payment is made shall be referred to herein as the Termination Effective Date. It is understood that the Upfront Payment is a firm obligation and is not contingent upon Revance raising additional funds or otherwise.

 3.2 Proceeds Sharing Payments. 
 (a) In addition to the Upfront Payment, Revance shall pay to Medicis an aggregate amount equal to Fourteen Million Dollars (US $14,000,000.00) (such amount as it may be reduced pursuant to
Section 3.5 the “Second Payment Amount”) by remitting to Medicis fifteen percent (15%) of any and all Cash Proceeds received by Revance, its Affiliates, and its and their successors and assigns within five
(5) business days of receipt of thereof (each such 15% remittance, a “Proceeds Sharing Payment”) until Revance has paid Medicis the total Second Payment Amount in Proceeds Sharing Payments pursuant to this Section 3.2.
Notwithstanding the foregoing, with respect to Cash Proceeds received pursuant to a Limited Initial Public Offering, the Proceeds Sharing Payment due hereunder shall be reduced to (i) ten percent (10%) of such Cash Proceeds if

  
 - 8 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 
such Cash Proceeds to Revance (after underwriting discounts and commissions and offering expenses) are less than Sixty Million Dollars (US $60,000,000) but equal to or greater than Forty Million
Dollars (US $40,000,000), and (ii) five percent (5%) of such Cash Proceeds if such Cash Proceeds are less than Forty Million Dollars (US $40,000,000). 
 (b) If, prior to Medicis’ receipt of the total Second Payment Amount in Proceeds Sharing Payments pursuant to this Section 3.2, Revance consummates: 

(i) an Acceleration Transaction as described in Section 1.1(a), 1.1(b) or 1.1(c) above, then the amount representing the difference
between (A) the Second Payment Amount (or $12,880,000 if such Acceleration Transaction occurs prior to the first anniversary of the Execution Date) and (B) the aggregate amount of Proceeds Sharing Payments paid by Revance to Medicis prior
to the consummation of the Acceleration Transaction (such amount, the “Acceleration Balance Amount”) shall become due and payable within five (5) business days after the consummation of the Acceleration Transaction; or

 (ii) An Acceleration Transaction as described in Section 1.1(d), 1.1 (e) or 1.1(f) above, then the amount equal to
the lesser of (A) the amount paid to a stockholder of Revance as described in Section 1.1(d), 1.1(e) or 1.1(f), as applicable, or (B) the Acceleration Balance Amount shall become due and payable within five (5) business days
after the consummation of the Acceleration Transaction. 
 (c) For clarity, the total amount of all Proceeds Sharing Payments
shall in no event exceed an aggregate, cumulative total of Fourteen Million Dollars (US $14,000,000), and once the total Second Payment Amount has been paid, Revance shall have no further obligations under this Section 3.2. 

3.3 Approval Milestone Payment. In addition to the Upfront Payment and the Second Payment Amount, Revance shall make a one-time
payment to Medicis of Four Million Dollars (US $4,000,000) (the “Approval Milestone Payment”) within thirty (30) days after the first receipt of Marketing Approval for a Product for the United States or a Major EU Market by
Revance, its Affiliate or licensee. Only one such payment shall be made, regardless of how many Products achieve Marketing Approval or how many Marketing Approvals are obtained, so that the total amount due under this Section 3.3 shall not
exceed Four Million Dollars (US $4,000,000). 
 3.4 Total Payments by Revance. In no event shall the cumulative total
amount payable by Revance to Medicis pursuant to this Termination Agreement, including Section 3.1, Section 3.2 and Section 3.3 hereof, collectively exceed Twenty-Five Million Dollars (US $25,000,000), plus any accrued interest due
pursuant to Section 3.5. 
 3.5 Payment Method; Prepayment. All payments pursuant to this Article III shall be made
by bank wire transfer in immediately available funds to an account designated in writing by Medicis. Revance shall have the right to prepay any amounts (or portions thereof) payable pursuant 

  
 - 9 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 
to Sections 3.1, 3.2 or 3.3 above without penalty. Notwithstanding Section 3.2, in the event Revance pays a total of Twelve Million Eight Hundred Eighty Thousand Dollars (US $12,880,000.00)
in Proceeds Sharing Payments prior to the first anniversary of the Execution Date, Revance shall have no further obligation hereunder to pay Proceeds Sharing Payments and the total Second Payment amount shall be deemed paid. In addition, in the
event that Revance pays a total of at least US $7,000,000 prior to the first anniversary of the Execution Date, the total remaining Second Payment Amount due hereunder shall be reduced by an amount equal to eight percent (8%) of the Proceeds
Sharing Payments made prior to the first anniversary of the Execution Date. Commencing on the third anniversary of the Execution Date, any unpaid balance of the Second Payment Amount shall accrue interest, from such date until paid, at an annual
rate equal to the lesser of (i) eight percent (8%) or (ii) the maximum rate permitted under Applicable Laws. 

3.6 Subordination Agreement. The payments to be made to Medicis pursuant to Sections 3.2 and 3.3 above are hereby expressly
subordinated in right of payment with respect to Existing Hercules Debt (including any Refinanced Loan) and, unless otherwise expressly provided in a subordination agreement with any lender of Existing Hercules Debt or refinanced Existing Hercules
Debt, no payment pursuant to Sections 3.2 or 3.3 above shall be made to Medicis in the event that a default or breach exists under the Existing Hercules Debt or any Refinanced Loan. Medicis agrees to execute and deliver to Hercules Capital the form
of Subordination Agreement attached hereto as Schedule 3.6 (the “Subordination Agreement”); and if Revance refinances Existing Hercules Debt, Medicis agrees to execute and deliver to the lender of such Refinanced Loan a form
of subordination agreement with respect to such Refinanced Loan as is commonly requested by such lender and to abide by the terms thereof. 
 3.7 Taxes. All excises, taxes, and duties (collectively “Taxes”) levied on account of a payment made by Revance to Medicis pursuant to this Article III will be the responsibility
of and paid by Medicis. If Taxes are required under Applicable Laws to be withheld by Revance in connection with any payment made hereunder, Revance shall (i) deduct those Taxes from the payment and (ii) pay the Taxes to the proper taxing
authority. In the event such taxing authorities routinely provide a Tax receipt upon payment, Revance will procure a receipt for any such withholding evidencing payment of such Taxes, which will be forwarded to Medicis. Medicis represents and
warrants that it is resident for tax purposes in the United States and agrees to provide upon request a properly completed Form W-9 or other tax form necessary to certify United States residency or claim a reduction of, or exemption from,
withholding. 
 ARTICLE IV 
 AMENDMENT OF EQUITY DOCUMENTS 
 4.1 Medicis Ownership of Revance
Preferred Stock. The Parties hereby acknowledge and agree that Medicis shall retain its ownership of the 2,173,913 shares of Series C-3 Preferred Stock of Revance and the 138,385 shares of Series D Preferred Stock of Revance, which the Parties
agree constitute all of the equity securities of Revance owned by Medicis immediately prior to the 

  
 - 10 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 
Execution Date (the “Revance Preferred Stock”), and that except as otherwise set forth in this Article IV and Schedules 4.2 and 4.3 attached hereto, Medicis’
ownership of and rights with respect to such Revance Preferred Stock shall not be changed as a result of this Termination Agreement. 
 4.2 Amendment of Revance Equity Rights Agreements. Medicis hereby consents to the amendments as of the Termination Effective Date to each of (a) the Revance Amended and Restated Co-Sale
Agreement dated as of December 8, 2009, by and among Revance and the investors and founders named as parties thereto (“Revance Co-Sale Agreement”), (b) the Revance Amended and Restated Investor Rights Agreement dated as of
December 8, 2009, as amended as of May 6, 2010, by and among Revance and the investors named as parties thereto (“Revance Investor Rights Agreement”), and (c) the Revance Amended and Restated Voting Agreement dated as
of December 8, 2009, as amended on December 11, 2011, by and among Revance and the key holders and investors named as parties thereto (“Revance Voting Agreement”, and collectively with the Revance Co-Sale Agreement and
Revance Investor Rights Agreement, the “Revance Equity Rights Agreements”), all as set forth in the form attached hereto as Schedule 4.2. To implement such consent, Medicis agrees to execute and deliver to Revance the form of
amendment to the Revance Equity Rights Agreements attached hereto as Schedule 4.2 concurrently with the execution of this Termination Agreement, provided that such amendment shall not be effective until the Termination Effective Date.

 4.3 Amendment of Revance Certificate of Incorporation. Medicis hereby consents to the amendment as of the Termination
Effective Date of the Revance Amended and Restated Certificate of Incorporation as filed with the Secretary of State of the State of Delaware on May 10, 2010 (the “Revance Certificate of Incorporation”) as set forth in
Schedule 4.3 hereto. To implement such consent, Medicis agrees to execute and deliver to Revance the form of consent attached hereto as Schedule 4.3 concurrently with the execution of this Termination Agreement, provided that such
amendment shall not be effective until the Termination Effective Date. 
 4.4 Amendment of Security Agreement. Medicis
hereby consents to the amendment as of the Termination Effective Date of the Security Agreement by and among Revance and the other parties named therein, dated as of January 24, 2011, to which Medicis is a third party beneficiary to
Section 5(h) thereunder, as set forth in the form attached hereto as Schedule 4.4. To implement such consent, Medicis agrees to execute and deliver to Revance the form of amendment to such Security Agreement attached hereto as
Schedule 4.4 concurrently with the execution of this Termination Agreement, provided that such amendment shall not be effective until the Termination Effective Date. 
 4.5 Further Assurances. Commencing as of the Termination Effective Date, Medicis hereby agrees to promptly execute and deliver, or cause to be executed and delivered, all consents, amendments to
the Revance Equity Rights Agreements and such further documents, certificates, agreements and instruments, and to take such further actions, as Revance may reasonably request, that are reasonably necessary for the purpose of carrying out and
furthering the intent and purposes of this Article IV of the Termination Agreement. 

  
 - 11 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 ARTICLE V 
 REPRESENTATIONS AND WARRANTIES 
 5.1 General Representations. Each
Party hereby represents and warrants to the other Party as of the Execution Date as follows: 
 (a) Such Party has been
represented by independent legal counsel of its own choosing in connection with this Termination Agreement, and has had adequate opportunity to consult with such counsel prior to the execution of this Termination Agreement. 

(b) This Termination Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms. The
execution, delivery and performance of this Termination Agreement by such Party have been duly authorized by all necessary corporate action and do not and will not: (i) require any consent or approval of its stockholders; (ii) to such
Party’s knowledge, violate any Applicable Laws, order, writ, judgment, decree, determination or award of any court, governmental body or administrative or other agency having jurisdiction over such Party; nor (iii) conflict with, or
constitute a default under, any agreement, instrument or understanding, oral or written, to which such Party is a party or by which it is bound. In particular, and without limiting the generality of the foregoing, each Party represents and warrants
to the other Party that it is fully entitled to grant the releases, enter into the covenants, and undertake the obligations set forth herein. 
 (c) Such Party has not sold, assigned, conveyed, pledged, encumbered, or otherwise in any way transferred to any Person any Claim released by such Party pursuant to this Termination Agreement. 

(d) Such Party has not filed, or is not aware that any Third Party has filed, any legal or administrative proceeding of any kind or
nature against the other Party, other than the Claims filed in the Litigation. 
 (e) Such Party is not relying in any manner on
any statement, promise, representation or omission, whether oral or written, express or implied, made by any person or entity, not specifically set forth in this Termination Agreement 

(f) Other than this Termination Agreement, the Subordination Agreement, the Terminated Agreements, the Revance Equity Rights Agreements,
the Series C Preferred Stock Purchase Agreement, the Series D Preferred Stock Purchase Agreement, and the Stipulation and Order Governing the Production and Exchange of Highly Confidential Information entered by the Chancery Court of the State of
Delaware on July 5, 2012 (collectively, the “Existing Agreements”), there are no other agreements, contracts or other legally binding commitments existing as of (or immediately prior to) the Execution Date between the Parties
or their Affiliates. If any such other 

  
 - 12 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 
agreements contracts or commitments exist as of the Execution Date (i.e., other than the Existing Agreements), such other agreements, contracts and commitments shall be deemed terminated as of
the Termination Effective Date. For clarity, the agreements listed on Schedule 5.1 shall not terminate. 
 ARTICLE VI

 CONFIDENTIALITY; PRESS RELEASE 
 6.1 Confidential Information. Except as expressly provided in this Termination Agreement, the Parties agree that the receiving Party shall not publish or otherwise disclose and shall not use for
any purpose any confidential or proprietary information or material furnished or made available to it by or on behalf of the other Party (i) prior to the Execution Date that was designated as confidential prior to the Execution Date or that the
receiving Party should reasonably understand to be confidential, or (ii) on or after the Execution Date that is designated as confidential or that the receiving Party should reasonably understand to be confidential ((i) and
(ii) collectively, “Confidential Information”). For clarity, all such information and materials that were received by a Party from the other Party in connection with the Existing Agreements shall be deemed to have been
furnished in connection with this Termination Agreement and shall be deemed Confidential Information with respect to the receiving Party. Notwithstanding the foregoing, Confidential Information shall not include information that, in each case as
demonstrated by written documentation: 
 (a) was already known to the receiving Party, other than under an obligation of
confidentiality, at the time of disclosure or, as shown by written documentation, was developed by the receiving Party prior to its disclosure by the disclosing Party; 
 (b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party; 

(c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act
or omission of the receiving Party in breach of this Termination Agreement or any other obligation of confidentiality between the Parties; 
 (d) was subsequently lawfully disclosed to the receiving Party, other than under an obligation of confidentiality, by a person other than the disclosing Party, and who did not directly or indirectly
receive such information from the other Party; or 
 (e) is developed by the receiving Party without use of or reference to any
Confidential Information received directly or indirectly from the other Party. 
 6.2 Permitted Disclosures.
Notwithstanding the provisions of Section 6.1 above and 6.3 below, the receiving Party may disclose Confidential Information of the other Party to the extent necessary to comply with Applicable Laws, including applicable court orders or other
legal process. 

  
 - 13 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 
If a Party proposes to make a disclosure of the other Party’s Confidential Information under this Section 6.2, to the extent it may legally do so, it will give reasonable advance notice
to the other Party of such disclosure and will use its good faith efforts to secure confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or otherwise). 

6.3 Confidentiality of Terms. Each Party agrees not to disclose to any Third Party the terms of this Termination Agreement,
without the prior written consent of the other Party hereto, except that, notwithstanding Sections 6.1 and 6.2 above, each Party may disclose the terms of this Termination Agreement: (a) to lenders (including Hercules Capital), advisors
(including financial advisors, attorneys and accountants), actual or potential acquirors, partners or private investors, and others on a need to know basis, in each case under appropriate confidentiality provisions consistent with the nature of the
information disclosed; or (b) to comply with Applicable Laws, including securities laws, regulations or guidances. Notwithstanding the foregoing, Revance may issue a press release in the form attached as Schedule 6.3(a) and Medicis may
make the filing with the description of the transaction attached hereto as Schedule 6.3(b) (collectively, the “Initial Releases”). The Parties acknowledge and agree the Initial Releases are the statements of the Party making
such release only and are not sanctioned by, admissions by, nor attributable to the other Party. Neither Party shall issue any press release nor make another public announcement of this Agreement or the transactions set forth herein, other than the
statements made in the Initial Releases and as reasonably required by applicable securities laws and regulations. After the issuance by the Parties of the Initial Releases, each Party may disclose without restriction the information contained in
either such Initial Release without the need for further approval by the other Party. 
 6.4 Return of Confidential
Information. Promptly following the Termination Effective Date, each Party shall promptly return or destroy all relevant documents or materials in its possession or control containing Confidential Information received from the other Party. As to
materials exchanged or produced in the Litigation, to the extent this provision is inconsistent with the Stipulation and Order Governing the Production and Exchange of Confidential and Highly Confidential Information entered by the Chancery Court of
the State of Delaware on July 5, 2012 (“Stipulation and Order”), the Stipulation and Order shall control 

ARTICLE VII 

GENERAL PROVISIONS 
 7.1 Governing Law. This Termination Agreement and all questions regarding its validity or interpretation, or the breach or performance of this Termination Agreement, shall be governed by, and
construed and enforced in accordance with, the laws of the State of Delaware, without reference to conflict of law principles. 

7.2 Venue; Jurisdiction for Disputes. The Parties agree that the sole jurisdiction, venue and dispute resolution procedure for all
disputes, controversies or claims (whether in contract, tort or otherwise) arising out of, relating to or otherwise by virtue of, this Termination Agreement, breach of this Termination Agreement or the transactions contemplated by this Termination
Agreement 

  
 - 14 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 
shall be the Delaware Court of Chancery within the State of Delaware (or, if the Delaware Court of Chancery lacks jurisdiction over a particular matter, any court of the United States located in
the State of Delaware or any state court located in the State of Delaware), and the parties to this Termination Agreement hereby consent to the jurisdiction of such court and waive any objection to the venue of such proceeding. Each of the parties
agrees that process may be served upon it in the manner specified in Section 7.8 below and irrevocably waives and covenants not to assert or plead any objection which it might otherwise have to such jurisdiction, or to such manner of service of
process. 
 7.3 Costs and Attorneys’ Fees. The prevailing Party in any suit or proceeding arising out of or
relating to this Termination Agreement shall be entitled to recover all of its costs and expenses, including reasonable attorneys’ fees, incurred in connection with such suit or proceeding, including any costs associated with collecting
payments due hereunder. 
 7.4 No Implied Obligations. THIS TERMINATION AGREEMENT EXPRESSLY SETS FORTH ALL RIGHTS AND
OBLIGATIONS OF THE PARTIES INTENDED HEREBY. NEITHER PARTY SHALL BE DEEMED TO HAVE ANY IMPLIED RIGHTS OR OBLIGATIONS WITH RESPECT TO ANY MATTERS CONTAINED HEREIN. 
 7.5 Modification. No amendment or modification of any provision of this Termination Agreement shall be effective unless in writing signed by a duly authorized representative of each Party. No
provision of this Termination Agreement shall be modified or amended by any oral agreement not set forth in an agreement in writing and signed by a duly authorized representative of each Party. 

7.6 Severability. In the event any provision of this Termination Agreement should be held invalid, illegal or unenforceable in any
jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions of this Termination Agreement shall remain in full
force and effect in such jurisdiction. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction. 

7.7 Entire Agreement. This Termination Agreement (including the Schedules attached hereto) constitutes the entire agreement
between the Parties relating to its subject matter and supersedes all prior or contemporaneous agreements, understandings or representations, either written or oral (including the Terminated Agreements) between Revance and Medicis with respect to
such subject matter. 
 7.8 Notices. Unless otherwise agreed by the Parties or specified in this Termination Agreement,
all communications between the Parties relating to, and all written documentation to be prepared and provided under, this Termination Agreement shall be in the English language. Any notice required or permitted under this Termination Agreement shall
be in writing in the English language: (a) delivered personally; (b) sent by registered or certified mail (return receipt requested 

  
 - 15 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 
and postage prepaid); (c) sent by express courier service providing evidence of receipt, postage pre-paid where applicable; or (d) sent by facsimile (receipt verified and a copy
promptly sent by another permissible method of providing notice described in paragraphs (b), (c) or (d) above), to the following addresses of the Parties or such other address for a Party as may be specified by like notice:

  

			
	 To Revance:
  

Revance, Inc.
 7555 Gateway Blvd
 Newark, CA 94560

Fax: (510) 742-3401
 Attention: Chief Financial Officer
	 	 To Medicis:
  

Medicis Pharmaceutical Corporation
 7720 North
Dobson Road
 Scottsdale, AZ 85256
 Fax:
(480) 291-8508
 Attention: General Counsel

		
	 With a copy to:
  

Keker & Van Nest LLP
 633 Battery Street
 San Francisco, CA 94111-1809

Fax: (415) 397-7188
 Attention: Stuart Gasner
  
 Wilson, Sonsini, Goodrich & Rosati
 650 Page Mill Road

Palo Alto, CA 94304
 Fax: (650) 493-6811
 Attention: Kenneth A. Clark
	 	 With a copy to:
  

Arnold & Porter LLP
 1600 Tysons Blvd., Suite
900
 McLean, VA 22101
 Fax: (703)
720-7399
 Attn: Susan E. Hendrickson

 Any notice required or permitted to be given concerning this Termination Agreement shall be effective
upon receipt by the Party to whom it is addressed or within seven (7) days of dispatch whichever is earlier. 
 7.9
Assignment. This Termination Agreement shall not be assigned or otherwise transferred by either Party to any Affiliate or any Third Party without the prior written consent of the other Party hereto, which consent shall not be unreasonably
withheld, conditioned or delayed; except that (i) Medicis may assign or otherwise transfer this Termination Agreement without such consent to any entity that acquires all or substantially all of the business or assets of Medicis to which this
Termination Agreement relates, whether by merger, acquisition or otherwise, provided that the entity to whom this Termination Agreement is assigned assumes this Termination Agreement in writing or by operation of law; and (ii) Revance may
assign or otherwise transfer this Termination Agreement without such consent to any entity that acquires all or substantially all of the business or assets of Revance to which this Termination Agreement relates, provided that the entity to whom this

  
 - 16 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 
Termination Agreement is assigned assumes this Termination Agreement in writing or by operation of law, and provided further that in the case of a Change of Control, prior to such assignment,
Medicis has been paid the Acceleration Balance Amount in full. For clarity, after any such assignment or transfer all cash payments and Marketable Securities that such assignee or other transferee and its Affiliates receive following such assignment
or transfer shall constitute Cash Proceeds (subject to the exclusions set forth in Section 1.5) hereunder until such time as the Second Payment Amount to Medicis hereunder has been satisfied in full. Furthermore, Medicis may assign its right to
receive payment hereunder to any Affiliate or other Third Party without consent. Subject to the foregoing, this Termination Agreement shall inure to the benefit of each Party, its successors and permitted assigns. Any assignment of this Termination
Agreement in contravention of this Section 7.9 shall be null and void. 
 7.10 Compromise Agreement. This
Termination Agreement is a compromise and settlement of disputed Claims and is not intended to be, nor shall be construed as, any admission of liability or wrongdoing by any Party. This Termination Agreement and any performance or conduct under this
Termination Agreement shall not be admissible in any arbitration, lawsuit, or other proceeding except as necessary to enforce the terms and conditions hereof. The Parties agree that this Termination Agreement fully resolves the Litigation. Medicis
and Revance each shall be responsible for their respective legal and other fees and expenses associated with all aspects of the Litigation, and the negotiation of this Termination Agreement and any other related agreements. 

7.11 Interpretation. The captions to the several Articles and Sections of this Termination Agreement are not a part of this
Termination Agreement, but are included for convenience of reference and shall not affect its meaning or interpretation. In this Termination Agreement: (a) the word “including” shall be deemed to be followed by the phrase
“without limitation” or like expression; (b) the singular shall include the plural and vice versa; and (c) masculine, feminine and neuter pronouns and expressions shall be interchangeable. All references to a “business
day” or “business days” in this Termination Agreement means any day other than a day which is a Saturday, a Sunday or any day banks are authorized or required to be closed in the United States. 

7.12 Counterparts. This Termination Agreement may be executed in any number of counterparts, each of which shall be deemed an
original, and all of which together shall constitute one and the same instrument. 
 [SIGNATURE PAGE FOLLOWS] 

  
 - 17 -

 EXECUTION VERSION 

CONFIDENTIAL 
  

 IN WITNESS WHEREOF, the Parties have executed this Termination Agreement as of the date
first set forth above. Each of the persons executing this Agreement represents that he/she is authorized to execute on behalf, and therefore to bind, the respective Parties below. 

REVANCE THERAPEUTICS, INC. 
  

			
	 BY:
	 	 /s/ L. Daniel Browne

			
	 NAME:
	 	L. Daniel Browne

			
	 TITLE:
	 	President and CEO

 MEDICIS PHARMACEUTICAL CORPORATION 

 

			
	 BY:
	 	 /s/ Richard Peterson

			
	 NAME:
	 	Richard Peterson

			
	 TITLE:
	 	CFO

  
 - 18 -

 EXECUTION VERSION 

CONFIDENTIAL 

Schedule 3.6 
 Subordination Agreement 
 [See Attached] 

 SUBORDINATION AGREEMENT 

This Subordination Agreement is made as of October      , 2012 by and among MEDICIS PHARMACEUTICAL CORPORATION
(“Creditor”), REVANCE THERAPEUTICS, INC. (“Borrower”), and HERCULES TECHNOLOGY GROWTH CAPITAL, INC. (the “Lender”). 
 Recitals 
 A. Borrower has requested and/or obtained certain loans or other
credit accommodations from Lender which are or may be from time to time secured by assets and property of Borrower pursuant to the terms of that certain Loan and Security Agreement dated September 20, 2011 by and between Borrower and Lender
(the “Loan Agreement”). 
 B. Creditor has agreed to accept a series of payments from Borrower pursuant to that
certain Settlement and Termination Agreement between Creditor and Borrower dated as of October      2012 (the “Settlement Agreement”). 
 C. Creditor is willing to subordinate: (i) all of Borrower’s payment obligations to such Creditor, whether presently existing or arising in the future under the Settlement Agreement (the
“Subordinated Debt”) to all of Borrower’s indebtedness and obligations to Lender; and (ii) all of Creditor’s security interests, if any, in Borrower’s property, to all of Lender’s security interests in the
Borrower’s property. 
 NOW, THEREFORE, THE PARTIES AGREE AS FOLLOWS: 

1. Creditor does not claim, will not demand, and has not been granted, any security interest in any assets of Borrower to secure the
obligations of Borrower under the Settlement Agreement. In the event that Creditor does obtain a security interest in, or lien on, any of Borrower’s assets, in violation of this Subordination Agreement or otherwise, Creditor subordinates to
Lender any security interest or lien that Creditor may have in any property of Borrower. Notwithstanding the respective dates of attachment or perfection of the security interest of Creditor and the security interest of Lender, the security interest
of Lender in the Collateral, as defined in the Loan Agreement, shall at all times be prior to the security interest of Creditor. Capitalized terms not otherwise defined herein shall have the same meaning as in the Loan Agreement. 

2. All Subordinated Debt is subordinated in right of payment to all obligations of Borrower to Lender now existing or hereafter arising,
together with all costs of collecting such obligations (including attorneys’ fees), including, without limitation, all interest accruing after the commencement by or against Borrower of any Bankruptcy, reorganization or similar proceeding, and
all obligations under the Loan Agreement (the “Senior Debt”). Notwithstanding the foregoing, Borrower may make, and Creditor may receive, payments that become due to Creditor after the date hereof in accordance with the Settlement
Agreement so long as no Event of Default under the Loan Agreement has occurred and then exists, or would result from any such payments. 

 3. Creditor will not exercise any remedy with respect to, or realize upon, the Collateral
for so long as any portion of the Senior Debt remains outstanding, provided (a) Creditor may bring an action against Borrower to compel performance under the Settlement Agreement and/or for the payment of damages for breach thereof, and obtain
a judgment in respect thereof, and (b) Creditor may convert any part of Subordinated Debt into equity securities of Borrower in accordance with the terms of the Settlement Agreement. 

4. Creditor shall promptly deliver to Lender in the form received (except for endorsement or assignment by such Creditor where required
by Lender) for application to the Senior Debt any payment, distribution, security or proceeds received by Creditor with respect to the Subordinated Debt other than in accordance with this Agreement. 

5. In the event of Borrower’s insolvency, reorganization or any case or proceeding under any Bankruptcy or insolvency law or laws
relating to the relief of debtors, these provisions shall remain in full force and effect, and Lender’s claims against Borrower and the estate of Borrower shall be paid in full before any payment is made to Creditor. 

6. For so long as any of the Senior Debt remains unpaid, Creditor irrevocably appoints Lender as Creditor’s attorney-in-fact, and
grants to Lender a power of attorney with full power of substitution, in the name of Creditor or in the name of Lender, for the use and benefit of Lender, without notice to Creditor, to perform at Lender’s option the following acts in any
Bankruptcy, insolvency or similar proceeding involving Borrower: 
 (i) To file the appropriate claim or claims in respect of
the Subordinated Debt on behalf of Creditor if Creditor does not do so prior to 30 days before the expiration of the time to file claims in such proceeding and if Lender elects, in its sole discretion, to file such claim or claims; and 

(ii) To accept or reject any plan of reorganization or arrangement on behalf of Creditor and to otherwise vote Creditor’s claims in
respect of any Subordinated Debt in any manner that Lender deems appropriate for the enforcement of its rights hereunder. 
 7.
Creditor shall immediately affix a legend to the instruments, if any, evidencing the Subordinated Debt stating that the instruments are subject to the terms of this Agreement. No amendment of the Settlement Agreement or other documents relating to
the Subordinated Debt shall directly or indirectly modify the provisions of this Agreement in any manner which might terminate or impair the subordination of the Subordinated Debt or the subordination of any security interest or lien that such
Creditor may have in any property of Borrower. By way of example, such documents shall not be amended to accelerate the timing of the payments due under the Settlement Agreement. 

8. This Agreement shall remain effective for so long as the Lender has any obligation to make credit extensions to Borrower or Borrower
owes any amounts to Lender under the Loan Agreement or otherwise. If, at any time after payment in full of the Senior Debt any payments of the Senior Debt must be disgorged by Lender for any reason (including, without limitation, the Bankruptcy of
Borrower), this Agreement and the relative rights and priorities set forth herein shall 

 
be reinstated as to all such disgorged payments as though such payments had not been made and Creditor shall immediately pay over to Lender all payments received with respect to the Subordinated
Debt to the extent that such payments would have been prohibited hereunder. At any time and from time to time, without notice to Creditor, Lender may take such actions with respect to the Senior Debt as Lender, in its sole discretion, may deem
appropriate, including, without limitation, terminating advances to Borrower, increasing the principal amount, extending the time of payment, increasing applicable interest rates, renewing, compromising or otherwise amending the terms of any
documents affecting the Senior Debt and any collateral securing the Senior Debt, and enforcing or failing to enforce any rights against Borrower or any other person. No such action or inaction shall impair or otherwise affect Lender’s rights
hereunder. 
 9. This Agreement shall bind any successors or assignees of Creditor and shall benefit any successors or assigns
of Lender. This Agreement is solely for the benefit of Creditor and Lender and not for the benefit of Borrower or any other party. Creditor further agrees that if Borrower is in the process of refinancing a portion of the Senior Debt with a new
lender, and if Lender makes a request of Creditor, Creditor shall agree to enter into a new subordination agreement with the new lender on substantially the terms and conditions of this Agreement. 

10. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall
constitute one instrument. 
 11. This Agreement shall be governed by, and construed in accordance with, the internal laws of
the State of California, without regard to principles of conflicts of law. Jurisdiction shall lie in the State of California. THE UNDERSIGNED ACKNOWLEDGE THAT THE RIGHT TO TRIAL BY JURY IS A CONSTITUTIONAL ONE, BUT THAT IT MAY BE WAIVED UNDER
CERTAIN CIRCUMSTANCES. TO THE EXTENT PERMITTED BY LAW, EACH PARTY, AFTER CONSULTING (OR HAVING HAD THE OPPORTUNITY TO CONSULT) WITH COUNSEL OF ITS, HIS OR HER CHOICE, KNOWINGLY AND VOLUNTARILY, AND FOR THE MUTUAL BENEFIT OF ALL PARTIES, WAIVES ANY
RIGHT TO TRIAL BY JURY IN THE EVENT OF LITIGATION ARISING OUT OF OR RELATED TO THIS AGREEMENT OR ANY OTHER DOCUMENT, INSTRUMENT OR AGREEMENT BETWEEN THE UNDERSIGNED PARTIES. If the jury waiver set forth in this Section is not enforceable, then any
dispute, controversy or claim arising out of or relating to this Agreement or any of the transactions contemplated herein shall be resolved by judicial reference pursuant to Code of Civil Procedure Section 638 et seq before a mutually
acceptable referee or, if none is selected, then a referee chosen by the Presiding Judge of the California Superior Court for Santa Clara County, provided this provision shall not restrict any party from seeking to enforce any prejudgment remedies.

 12. This Agreement represents the entire agreement with respect to the subject matter hereof, and supersedes all prior
negotiations, agreements and commitments. Creditor is not relying on any representations by Lender or Borrower in entering into this Agreement, and Creditor has kept and will continue to keep itself fully apprised of the financial and other
condition of Borrower. This Agreement may be amended only by written instrument signed by Creditor and Lender. 

 13. In the event of any legal action to enforce the rights of a party under this Agreement,
the party prevailing in such action shall be entitled, in addition to such other relief as may be granted, all reasonable costs and expenses, including reasonable attorneys’ fees, incurred in such action. 

[SIGNATURE PAGE FOLLOWS] 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first above
written. 
  

			
	“Lender”	 	
	
	HERCULES TECHNOLOGY GROWTH CAPITAL, INC.

 
			
		
	By:	 	  

			
	Title:	 	  

			
		
	“Borrower”	 	
	
	REVANCE THERAPEUTICS, INC.

 
			
		
	By:	 	  

			
	Title:	 	  

			
		
	“Creditor”	 	
	
	MEDICIS PHARMACEUTICAL CORPORATION

 
			
		
	By:	 	  

			
	Title:	 	  

 Schedule 4.2 
 Amendment to Revance Equity Rights Agreements 
 [See Attached] 

 REVANCE THERAPEUTICS, INC. 

OMNIBUS AMENDMENT TO AMENDED AND RESTATED 
 INVESTOR RIGHTS AGREEMENT, AMENDED AND RESTATED 
 VOTING AGREEMENT AND
AMENDED AND RESTATED 
 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT 

This Omnibus Amendment to Amended and Restated Investor Rights Agreement, Amended and Restated Voting Agreement and Amended and Restated
Right of First Refusal and Co-Sale Agreement (this “Amendment”) is entered into as of October     , 2012 by and between Revance Therapeutics, Inc., a Delaware corporation (the “Company”), and the
undersigned parties (the “Requisite Holders”). 
 WHEREAS, the
Company and the Requisite Holders are bound by the terms of the Amended and Restated Voting Agreement as amended on December 8, 2011 (the “Voting Agreement”), Amended and Restated Right of First Refusal and Co-Sale Agreement
(the “Co-Sale Agreement”) and, with respect to the Company and Investors only, the Amended and Restated Investors’ Rights Agreement as amended May 6, 2010 (the “Rights Agreement” and together with the
Co-Sale Agreement and Voting Agreement, the “Agreements”) each originally dated as of December 8, 2009, which, among other things, provide certain rights to and obligations on the holders of the Company’s Common Stock,
Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock Series C-1 Preferred Stock, Series C-2 Preferred Stock, Series C-3 Preferred Stock and Series D Preferred Stock; 

WHEREAS, pursuant to the terms thereof, the Company and the holders of at least a majority of the
Registrable Securities (as such term is defined in the Rights Agreement) then outstanding, and holders of a majority of the Series C-3 Preferred Stock to the extent adversely affected in a manner different than other holders, may amend the Rights
Agreement, and all such required shares are held by the undersigned Requisite Holders; 

WHEREAS, pursuant to the terms thereof, (i) the Company, (ii) holders of a majority of the
Series D Stock (iii) holders of a majority of the Series C Stock (iv) holders of a majority of the Series B Stock, (v) holders of a majority of the Key Holder Shares (as defined in the Voting Agreement) held by Key Holders as defined
in the Voting Agreement) then providing services to the Company as officers or employees and (v) other holders with respect to amendments or waivers to the section providing for their board designation rights, may amend the Voting Agreement,
and all such required shares are held by the undersigned Requisite Holders; 
 WHEREAS,
pursuant to the terms thereof, (i) the Company, (ii) a majority in interest of the Investor Stock (as defined in the Co-Sale Agreement) held by the Investors (as defined in the Co-Sale Agreement) and their assignees, pursuant to
Section 6.4 of the Co-Sale Agreement, and (iii) a majority in interest of the shares of Founder Stock (as defined in the Co-Sale Agreement) held by the Founders (as defined in the Co-Sale Agreement) then providing services to the Company
as an officer, employee or consultant, and all such required shares are held by the undersigned Requisite Holders; 

  
 1 

 WHEREAS, this Amendment is entered into in connection
with that certain Settlement and Termination Agreement by and between the Company and Medicis (the “Termination Agreement”) on or about the date hereof whereby, among other things, certain of Medicis’ rights with regard to its
ownership of Series C-3 Preferred Stock and Series D Preferred Stock of the Company will be terminated; and 

WHEREAS, such termination of rights requires an amendment to the Agreements and the Company and the Requisite
Holders desire to amend the Agreements as provided herein. 
 NOW,
THEREFORE, in consideration of the mutual promises and covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree
as follows: 
 AGREEMENT 
 1. Section 3.1(b) of the Rights Agreement is hereby amended and restated to read in its entirety as follows: 
 “(b) So long as an Investor (with its affiliates), shall own at least twelve and one half percent (12.5%) of the outstanding shares of Series A Stock, twelve and one half percent
(12.5%) of the outstanding shares of Series B Stock, twelve and one half percent (12.5%) of the outstanding shares of Series C-1 Stock and Series C-2 Stock considered together as a single class (each as adjusted for stock splits and
combinations) (or in the case of Shepherd Ventures II, L.P. (“Shepherd”), Palo Alto Investors and PAC-LINK Bio Venture Capital Investment Corporation, so long as such Investor holds shares of Company Preferred Stock having an
aggregate original issue price of at least $499,000), or twelve and one half percent (12.5%) of the outstanding shares of Series D Stock (a “Major Investor”), the Company will furnish each such Major Investor:
(i) at least thirty (30) days prior to the beginning of each fiscal year an annual budget and operating plans for such fiscal year (and as soon as available, any subsequent written revisions thereto), in form and substance reasonably
acceptable to the Major Investors; and (ii) as soon as practicable after the end of each quarter, and in any event within thirty (30) days thereafter, a balance sheet of the Company as of the end of each such quarter, and a statement of
income and a statement of cash flows of the Company for such quarter and for the current fiscal year to date, including a comparison to plan figures for such period, prepared in accordance with generally accepted accounting principles consistently
applied, with the exception that no notes need be attached to such statements and year-end audit adjustments may not have been made.” 
 2. Section 3.17(c) of the Rights Agreement is hereby amended and restated to read in its entirety as follows: 
 “(c) Reserved” 

  
 2 

 3. Section 5.5(a) of the Rights Agreement is hereby amended and restated to read in its
entirety as follows: 
 “(a) Except as otherwise expressly provided, this Agreement may be amended or modified only upon the
written consent of the Company and the holders of at least a majority of the then-outstanding Registrable Securities.” 

4. Section 1.4 of the Co-Sale Agreement is hereby amended and restated to read in its entirety as follows: 

“Major Investor” shall mean each investor (with its affiliates) who holds at least
(i) twelve and one-half percent (12
 1/2%) of the outstanding shares of Series A Stock, (ii) twelve and one-half percent (12  1/2%) of the outstanding shares of Series B Stock, (iii) twelve and one half percent
(12.5%) of the outstanding shares of Series C-1 Stock and Series C-2 Stock considered together as a single class (each as adjusted for stock splits and combinations occurring after the date hereof), or in the case of Shepherd Ventures II, L.P.,
Palo Alto Investors and PAC-LINK Bio Venture Capital Investment Corporation, so long as such investor holds shares of Company Preferred Stock having an aggregate original issue price of at least $499,000; or (iv) twelve and one-half percent (12
 1/2%) of the outstanding shares of Series D Stock. For purposes of this Agreement, an individual, firm, corporation, partnership, association, limited liability company, trust or any other entity
(collectively, a “Person”) shall be deemed an “Affiliate” of another Person who, directly or indirectly, controls, is controlled by or is under common control with such Person, including, without
limitation, any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management
company with, such Person. 
 5. Section 1.2(c) of the Voting Agreement is hereby amended and restated
to read in its entirety as follows: 
 “(c) Reserved” 

6. Section 1.9 of the Voting Agreement is hereby amended and restated to read in its entirety as follows: 

“Change of Control. In the event that the Company’s Board of Directors and the holders of at least fifty five percent
(55%) of then outstanding Preferred Stock, voting together as a single class on an as-converted to Common Stock basis (the “Requisite Holders”), approve a sale of the Company, in a single transaction or

  
 3 

 
series of related transactions or the sale of all or substantially all of the Company’s assets, in a single transaction or series of related transactions (an “Approved
Sale”) whether by means of a merger, consolidation or sale of stock or assets, or otherwise (each, a “Sale of the Company”), (i) if the Approved Sale is structured as a merger or consolidation of the
Company, or a sale of all or substantially all of the Company’s assets, each Key Holder and Investor agrees to be present, in person or by proxy, at all meetings for the vote thereon, to vote all shares of capital stock held by such person for
and raise no objections to such Approved Sale, and waive and refrain from exercising any dissenters rights, appraisal rights or similar rights in connection with such merger, consolidation or asset sale, or (ii) if the Approved Sale is
structured as a sale of the stock of the Company, the Key Holders and Investors shall each agree to sell their Key Holder Shares and Investor Shares on the terms and conditions approved by the Requisite Holders. Notwithstanding the foregoing, the
Key Holders and Investors (collectively, the “Stockholders”) shall not be required to vote their respective Key Holder Shares and/or Investor Shares in favor of the Approved Sale or agree to sell their respective Key Holder
Shares and/or Investor Shares in connection with an Approved Sale pursuant to this Section 1.9, as the case may be, unless (a) the terms of the Approved Sale do not provide that any such Stockholder would receive as a result of such
Approved Sale less than the amount that would be distributed to such Stockholder in the event the proceeds of the Approved Sale were distributed in accordance with the liquidation preferences set forth in the Restated Certificate, (b) any
representations and warranties required to be made by such Stockholder in connection with the Approved Sale are limited to representations and warranties made severally, and not jointly, by such Stockholder and are further limited to the
representations and warranties related to authority, ownership and the ability to convey titled to shares owned, (c) the Stockholder shall not be liable for the inaccuracy of any representation or warranty made severally by any other
Stockholder in connection with the Approved Sale, (d) the liability for indemnification, if any, of such Stockholder in the Approved Sale and for the inaccuracy of any representations and warranties made by the Company in connection with the
Approved Sale, shall be several and not joint with any other Stockholder and shall be pro rata in proportion to the amount of consideration paid to such Stockholder in connection with the Approved Sale (in accordance with the provisions of the
Restated Certificate) and (e) the liability shall be limited to such Stockholder’s applicable share of negotiated aggregate indemnification amount that applies equally to all Stockholders but that in no event exceeds the amount of
consideration otherwise payable to such Stockholder in connection with such Approved Sale, except with respect to claims related to fraud by the Stockholder. Notwithstanding anything in this Agreement, including, without limitation, this
Section 1.9, to the contrary, Medicis shall not be required in connection with any Approved Sale to agree pursuant to this Section 1.9 to (1) any noncompetition or similar covenant or agreement; (2) any other covenant or
agreement that would directly restrict the business of Medicis or any of its Affiliates other than for customary restrictions generally applicable to the Stockholders, such as confidentiality and related provisions; or (3) release or waive any
rights or claims unrelated to the Approved Sale against any Person.” 

  
 4 

 7. Section 3.5 of the Voting Agreement is hereby amended and restated to read in its
entirety as follows: 
 “Amendment or Waiver. This Agreement may be amended or modified (or provisions of this
Agreement waived) only upon the written consent of (i) the Company, (ii) holders of a majority of the Series D Stock (iii) holders of a majority of the Series C Stock (iv) holders of a majority of the Series B Stock and
(v) holders of a majority of the Key Holder Shares held by Key Holders then providing services to the Company as officers or employees. Any amendment or waiver so effected shall be binding upon the Company, each of the parties hereto and any
assignee of any such party provided, however, that notwithstanding the foregoing, (i) Section 1.2(a)(i) of this Agreement shall not be amended or waived without the written consent of Essex Eight, (ii) Section 1.2(b) of
this Agreement shall not be amended or waived without the written consent of Essex Five, (iii) the last sentence of Section 1.9 of this Agreement shall not be amended or waived without the written consent of Medicis,
(iv) Section 1.2(d)(i) of this Agreement shall not be amended or waived without the written consent of Vivo, and (v) Section 1.2(d)(ii) of this Agreement shall not be amended or waived without the written consent of Technology
Partners. Notwithstanding the foregoing, this Agreement may be amended to add holders of additional shares of Common Stock or Preferred Stock as “Key Holders” or “Investors” hereunder by an instrument in writing signed by the
Company and such holders.” 
 8. Except as expressly set forth herein, the Agreements shall remain in full force and effect
and shall not be modified or altered in any other way. 
 9. This Amendment may be executed in one or more counterparts, each of
which shall be deemed an original and all of which together shall constitute one instrument. 
 [Remainder of Page Intentionally
Left Blank] 

  
 5 

 IN WITNESS WHEREOF, the
parties hereto have executed this OMNIBUS AMENDMENT as of the date first above written. 
  

			
	COMPANY:	 	
	
	REVANCE THERAPEUTICS, INC.

			
		
	By:	 	  

			
	L. Daniel Browne,
	President and Chief Executive Officer
	
	KEY HOLDERS/FOUNDERS (PROVIDING SERVICES TO
THE COMPANY):
	
	  

	L. DANIEL BROWNE
	
	  

	JACOB M. WAUGH, M.D.
	
	STOCKHOLDERS:
	
	[INSERT STOCKHOLDER NAME]

			
		
	By:	 	  

			
	Name:	 	  

			
	Title:	 	  

  
 6 

 EXECUTION VERSION 

CONFIDENTIAL 

Schedule 4.3 
 Stockholder Consent Amending Revance Certificate of Incorporation 
 [See
Attached] 

  
 1 

 ACTION BY WRITTEN CONSENT 

OF THE STOCKHOLDERS 
 OF 
 REVANCE THERAPEUTICS, INC. 

The undersigned stockholders of REVANCE THERAPEUTICS, INC., a Delaware
corporation (the ‘Company’), pursuant to Sections 228 and 242 of the Delaware General Corporation Law (the ‘DGCL’), hereby vote all shares of voting stock of the Company held by them to adopt the
following resolutions by written consent: 
 CERTIFICATE OF AMENDMENT TO
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION 
 WHEREAS, the Company’s Board of Directors (the “Board”) has declared the advisability of amending the Company’s Amended and Restated Certificate of
Incorporation (the “Restated Certificate”) to, among other things, terminate certain of Medicis Pharmaceutical Corporation (“Medicis”) rights with regard to its ownership of Series C-3 Preferred Stock
and Series D Preferred Stock of the Company; 
 WHEREAS, pursuant to Section
D(2)(b)(i) of Article IV of the Restated Certificate, the Company shall not amend any provision of the Restated Certificate unless approved by the written consent or affirmative vote of at least a majority of the outstanding shares of the
Company’s Preferred Stock voting together as a single class; 

WHEREAS, pursuant to Section D(2)(e)(i) of Article IV of the Restated Certificate,
the Company shall not amend any provision of the Restated Certificate in any manner that alters or changes the voting or other power, preference or other special rights, privileges or restrictions on the Series C-3 Preferred Stock so as to affect
them adversely in a manner different than other classes of stock unless approved by the written consent or affirmative vote of at least a majority of the outstanding shares of the Company’s Series C-3 Preferred Stock voting together as a single
class; and 
 WHEREAS, the undersigned stockholders hold at least a majority
of the outstanding shares of Company’s Preferred Stock and at least a majority of the outstanding shares of the Company’s Series C-3 Preferred Stock. 
 NOW THEREFORE BE IT RESOLVED, that the Certificate of Amendment to the Restated Certificate in the form attached hereto
as Exhibit A, be, and it hereby is, adopted and approved in all respects (the “Certificate of Amendment”); and 

  
 1 

 RESOLVED FURTHER, that the officers of
the Company be, and each of them hereby is, authorized and directed, for and on behalf of the Company to file the Certificate of Amendment with the Delaware Secretary of State in the form and manner as required by the laws of the State of Delaware
and with such changes as the Delaware Secretary of State may require. 
 GENERAL AUTHORIZING
RESOLUTION 
 RESOLVED, that the appropriate officers of the Company be,
and each of them hereby is, authorized and directed, for an on behalf of the Company, to make such filings and applications, to execute and deliver such documents and instruments, and to do such acts and things as such officer deems necessary or
advisable in order to implement the foregoing resolutions; 
 RESOLVED
FURTHER, that the officers of the Company be, and each of them hereby is, authorized and directed, for an on behalf of the Company, to take such further action and execute such additional items as each may deem necessary or
appropriate to carry out the purposes of the above resolutions; and 
 RESOLVED
FURTHER, that any actions by any officer of the Company previously taken in furtherance of these resolutions are hereby ratified and approved. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 2 

 IN WITNESS WHEREOF, the undersigned has
executed this ACTION BY WRITTEN CONSENT OF THE STOCKHOLDERS of REVANCE
THERAPEUTICS, INC. as of the      day of October, 2012. 
  

			
	[INSERT STOCKHOLDER NAME]

 
			
		
	By:	 	  

 

			
	Print Name:	 	

 
			
	Title:	 	

  
 3 

 EXHIBIT A 
 CERTIFICATE OF AMENDMENT OF THE 
 AMENDED AND RESTATED CERTIFICATE OF
INCORPORATION 
 OF 
 REVANCE THERAPEUTICS, INC. 
 REVANCE
THERAPEUTICS, INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: 

FIRST: The name of the corporation is Revance Therapeutics, Inc. (the “Corporation”).

 SECOND: The original name of this company is Essentia Biosystems, Inc. and the date of filing the
original Certificate of Incorporation of this company with the Secretary of State of the State of Delaware was August 10, 1999. 
 THIRD: The Board of Directors of the Corporation, acting in accordance with the provisions of Sections 141 and 242 of the DGCL, adopted resolutions amending its Amended and
Restated Certificate of Incorporation as follows: 
 1. Article IV Section D(2)(e)(i) of the Amended and Restated
Certificate of Incorporation of the Corporation is hereby amended and restated to read as follows: 
 “(i) Any
amendment, alteration, or repeal of any provision of the Certificate of Incorporation of the Company, that alters or changes the voting or other powers, preferences, or other special rights, privileges or restrictions of the Series C-3 Preferred
Stock so as to affect them adversely in a manner different than other classes or series of stock (provided that any such amendment, alteration or repeal that alters or changes the voting or other powers, preferences, or other special rights,
privileges or restrictions of all of the Series C Preferred Stock, or all of the Series Preferred, in a proportional manner, shall not be deemed to affect the Series C-3 Preferred Stock adversely in a manner different than the other series of such
class); or” 
 2. Article IV Section D(2)(g)(iii) of the Amended and Restated Certificate of Incorporation of the
Corporation is hereby amended and restated to read as follows: 
 “(iii) Reserved.” 

  
 4 

 3. Article IV Section D(5)(l)(i) of the Amended and Restated Certificate of
Incorporation of the Corporation is hereby amended and restated to read as follows: 
 “(i) Each share of Series
Preferred shall automatically be converted into shares of Common Stock, based on the then-effective Series Preferred Conversion Price, (A) at any time upon the affirmative election of the holders of at least a majority of the outstanding shares
of the Series Preferred, (B) immediately upon the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of Common Stock for the
account of the Company (a “Public Offering”), upon the affirmative election of the holders of at least a majority of the outstanding shares of the Series Preferred, or (C) immediately upon the closing of a Public
Offering in which the per share price is at least $13.35 (as adjusted for stock splits, dividends, recapitalizations and the like after the filing date hereof), and the gross cash proceeds to the Company (before underwriting discounts, commissions
and fees) are at least $50,000,000 (in each case, a “Qualified Public Offering”).” 

FOURTH: Thereafter, pursuant to a resolution by the Board of Directors, this Certificate of Amendment of Amended
and Restated Certificate of Incorporation was submitted to the stockholders of the Company for their approval in accordance with the provisions of Section 228 and 242 of the DGCL. Accordingly, said proposed amendment has been adopted in
accordance with Section 242 of the DGCL. 

  
 5 

 EXECUTION VERSION 

CONFIDENTIAL 

Schedule 4.4 
 Amendment to Security Agreement 
 [See Attached] 

 AMENDMENT TO SECURITY AGREEMENT 

This AMENDMENT TO SECURITY AGREEMENT (the “Agreement”) is made and entered into as of October      ,
2012, by and among ReVance Therapeutics, Inc., a Delaware corporation (the “Debtor”) and the undersigned parties. 
 RECITALS 
 WHEREAS, pursuant to the terms of that certain Note and Warrant
Purchase Agreement dated as of January 24, 2011 by and among the Debtor and the purchasers party thereto (as amended, restated, modified or supplemented and in effect from time to time, the “Purchase Agreement”), the Debtor has
issued certain promissory notes (the “Notes”); 
 WHEREAS, the obligations of the Debtor to the holders of the
Notes (the “Note Holders”) are secured pursuant to that certain Security Agreement by and among the Debtor and the Note Holders dated as of January 24, 2011 (as amended, restated, modified or supplemented and in effect from
time to time, the “Security Agreement”); 
 WHEREAS, the Debtor has entered into that certain Settlement and
Termination Agreement by and between Debtor and Medicis Pharmaceutical Corporation (“Medicis”) on or about the date hereof (the “Termination Agreement”) whereby, among other things, certain of Medicis’ rights
set forth in the Security Agreement will be terminated; and 
 WHEREAS, the termination of such rights requires an amendment to
the Security Agreement, and the Company, the undersigned Note Holders constituting the Requisite Holders (as defined in the Purchase Agreement) and Medicis desire to amend the Security Agreement as provided herein. 

NOW, THEREFORE, in consideration of the mutual promises and covenants herein
contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
 1. Section 5(h) to the Security Agreement is amended and restated in its entirety to read as follows: 
 “(h) [Intentionally Deleted].” 
 2. This Amendment may be executed in
any number of counterparts and by the different parties hereto on separate counterparts, and each such counterpart shall be deemed to be an original, but all such counterparts shall together constitute one and the same Amendment. Delivery by
facsimile transmission or electronic mail transmission of an executed counterpart hereof shall have the same effect as delivery of an originally executed counterpart hereof. 
 [SIGNATURE PAGES FOLLOW] 

  
 1 

 IN WITNESS
WHEREOF, the parties hereto have executed this AMENDMENT TO SECURITY AGREEMENT as of the date set forth in the first
paragraph hereof. 
  

			
	REVANCE THERAPEUTICS, Inc.,
	a Delaware corporation

 
			
		
	By:	 	  

		 	L. Daniel Browne,
		 	President and Chief Executive Officer
	
	MEDICIS PHARMACEUTICAL
CORPORATION

 
			
		
	    BY:	 	  

			
	    NAME:	 	  

			
	    TITLE:	 	  

			
	
	[INSERT NOTE HOLDER NAME]

			
		
	    BY:	 	  

			
	    NAME:	 	  

			
	    TITLE:	 	  

  
 2 

 EXECUTION VERSION 

CONFIDENTIAL 

Schedule 5.1 
 Surviving Agreements Between the Parties 
 Revance Series C-1, C-2 and C-3 Preferred Stock
Purchase Agreement dated December 11, 2007 
 Revance Series D Preferred Stock Purchase Agreement dated December 8, 2009 

Revance Amended and Restated Co-Sale Agreement dated as of December 8, 2009, by and among Revance and the investors and founders named as parties
thereto 
 Revance Amended and Restated Investor Rights Agreement dated as of December 8, 2009, as amended on May 6, 2010, by and
among Revance and the investors named as parties thereto 
 Revance Amended and Restated Voting Agreement dated as of December 8, 2009, as
amended on December 11, 2011, by and among Revance and the key holders and investors named as parties thereto 
 Stipulation and Order
Governing the Production and Exchange of Highly Confidential Information entered by the Chancery Court of the State of Delaware on July 5, 2012 

 EXECUTION VERSION 

CONFIDENTIAL 

Schedule 6.3(a) 
 Press Release 
 [See Attached] 

					
	NEWS	 		 	FOR IMMEDIATE RELEASE

 CONTACT: 
 Revance Therapeutics, Inc. 
 Niquette L. Hunt 

Senior Vice President, Commercial Development 

(510) 742-3464 
 REVANCE
THERAPEUTICS REGAINS ALL WORLDWIDE RIGHTS TO ITS 
 BOTULINUM TOXIN PRODUCTS 

NEWARK, Calif.—October XX, 2012 — Revance Therapeutics, Inc. (Revance) today announced a settlement and termination agreement for
its contractual relationships with Medicis Pharmaceutical Corporation (NYSE: MRX) concerning RT001 Botulinum Toxin Type A Topical Gel and RT002 injectable Botulinum Toxin Type A. As part of the settlement, all worldwide rights to develop and
commercialize both products across all indications will be returned to Revance. The agreement will also resolve the outstanding litigation between the companies. 
 Under the terms of the agreement, Revance will make an upfront payment to Medicis of $7 million and up to an additional $18 million based on certain events. In return, the RT001 Option Agreement and
related agreements, and the 2009 RT002 License Agreement will be terminated in their entirety. Medicis will retain its current equity ownership in Revance. Additional terms of the agreement were not disclosed. 

Following the effective date of the agreement, Revance will be moving forward with the Phase 3 program for RT001 in the lead aesthetic indication. RT001
has reached End of Phase 2 with the FDA after studying more than 550 patients in eleven clinical trials. Collectively, these trials showed that RT001 demonstrated statistically significant efficacy with a strong safety profile. Revance is also
pursuing clinical development of RT001 for therapeutic indications. 
 In addition, Revance will be initiating the Phase 1/2 program for RT002.
RT002 is a next generation injectable designed to provide greater safety and efficacy than currently available injectable botulinum toxin products. 
 “We are tremendously excited about recovering all global rights to our product portfolio. This independence and our entrepreneurial corporate culture will keep fueling scientific innovation and
progress,” said Dan Browne, President and Chief Executive Officer of Revance. “Controlling the development and commercialization of these innovative compounds will allow us to leverage our groundbreaking neuromodulation platform and
maximize the value of our botulinum toxin franchise.” 
 About RT001 and RT002 

RT001 Botulinum Toxin Type A Topical Gel is an investigational product whose first aesthetic indication is designed to reduce crow’s feet wrinkles by
temporarily relaxing the muscle around the eyes. Based on clinical results, Revance’s goal is to expand the market beyond injectable treatments which, despite their popularity, have only captured about 10% of the potential market. Revance
believes that offering a safe, efficacious and painless procedure will appeal to many consumers who have considered treatment but are uncomfortable with the pain and bruising associated with injectables. RT001 is currently being studied for the
treatment of lateral canthal lines (crow’s feet) and the therapeutic indications of hyperhidrosis (excessive sweating) and migraine headaches. 

 RT002 is an investigational, next-generation, injectable neurotoxin that integrates
Revance’s proprietary, purified botulinum toxin type A molecule with the patented TransMTS® peptide
technology. Pre-clinical data suggests the TransMTS technology may enhance delivery of the drug to the target which may positively affect duration of effect and safety profile. 
 About Revance Therapeutics, Inc. 
 Revance Therapeutics, Inc. (Revance)
is a privately held specialty biopharmaceutical company which develops next generation products in dermatology and therapeutic medicine. Revance has developed a platform technology, TransMTS® that enables local, targeted delivery of botulinum toxin and other potent macromolecules across skin without patches, needles or other invasive procedures.

 Revance is backed by a blue chip roster of healthcare venture capital investors, including Essex Woodlands Health Ventures, Vivo Ventures,
Technology Partners, NovaQuest Capital Management, Shepherd Ventures, Palo Alto Investors, Bio*One Capital and Pac-Link Ventures. For more information, see the company website at www.revance.com 

 EXECUTION VERSION 

CONFIDENTIAL 

Schedule 6.3(b) 
 Filing 
 [See Attached] 

 MRX 8-K DRAFT FILING: 

On October [—], 2012, Medicis Pharmaceutical Corporation (the “Company”)
entered into a Settlement and Termination Agreement (the “Agreement) with Revance Therapeutics, Inc. (“Revance”) to settle litigation and terminate certain contractual relationships between the Company and Revance. 

Pursuant to the terms of the Agreement, (i) the option to acquire Revance or to exclusively license certain of Revance’s
topical botulinum toxin products purchased by the Company on December 11, 2007 and (ii) the License Agreement dated July 28, 2009 between the Company and Revance are terminated. In accordance with the Agreement, the previously
disclosed litigation filed by Revance against the Company in the Court of Chancery of the State Delaware will be dismissed with prejudice and all claims under the terminated agreements, whether known or unknown, are released. The Agreement also
provides for an upfront payment to the Company of $7 million to be made within 30 days of the Agreement, payments to the Company of up to $14 million to be made upon certain Revance capital raising achievements and a payment to the Company of $4
million to be made upon the achievement of certain regulatory milestones. The Company will maintain its minority ownership interest in Revance.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]